denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
M Rivera-Franco, M.
M.Hosseini, M.
Ma, E.
277 - Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US
4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
4956 - Burden of Illness in Patients with Higher-Risk Myelodysplastic Syndromes By Baseline Transfusion Status
4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
4956 - Burden of Illness in Patients with Higher-Risk Myelodysplastic Syndromes By Baseline Transfusion Status
Ma, F.
Ma, H.
1838 - MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism
3267 - Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice
4459 - The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease
3267 - Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice
4459 - The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease
Ma, J.
Ma, J.
1624 - A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma
2945 - Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma
2945 - Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma
Ma, J.
1204 - Machine Learning Applications for Prediction of Blood Transfusion and Survival in Acute Myeloid Leukemia
4039 - Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Adults with Acute Myeloid Leukemia
4400 - Application of Newly Developed IPSS-M and Comparison of Different Prognostic Systems in Patients with Myelodysplastic Syndrome
4039 - Combined Molecular and Clinical Prognostic Index for Relapse and Survival in Adults with Acute Myeloid Leukemia
4400 - Application of Newly Developed IPSS-M and Comparison of Different Prognostic Systems in Patients with Myelodysplastic Syndrome
Ma, J.
2587 - Human Models of NUP98-Rearranged Leukemia Reveal Fusion-Specific Molecular Mechanisms
2589 - Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7
3906 - Tracking Clonal Evolution in Pediatric AML
3930 - UBTF-TD Expression Is Necessary and Sufficient for Myeloid Cell Expansion
4141 - The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia
2589 - Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7
3906 - Tracking Clonal Evolution in Pediatric AML
3930 - UBTF-TD Expression Is Necessary and Sufficient for Myeloid Cell Expansion
4141 - The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia
Ma, L.
1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe
1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
Ma, L.
Ma, L.
1099 - Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial
1450 - Venetoclax Plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
3066 - The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
4389 - EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
1450 - Venetoclax Plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
3066 - The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
4389 - EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
Ma, M.
Ma, M.
Ma, N.
Ma, P.
Ma, Q.
Ma, Q.
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
2310 - Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020
2321 - Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
2310 - Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020
2321 - Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
Ma, S.
Ma, S.
154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1666 - Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
2970 - Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1666 - Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
2970 - Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
Ma, S.
Ma, T.
209 - Genetic and Pharmacological Inhibition of BTK Increases Dasatinib Sensitivity in Vitro and In Vivo Including CNS-Infiltrating E2A-PBX1+/Pre-BCR+ ALL Cells
1466 - Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
4092 - Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)
1466 - Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
4092 - Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)
Ma, W.
2076 - Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Gvhd (aGVHD) and Overall Survival after Allogeneic HSC Transplantation
2789 - DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy
3488 - Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA
2789 - DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy
3488 - Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA
Ma, X.
Ma, X.
2309 - Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma
4003 - Racial and Ethnic Disparities in Childhood Acute Lymphoblastic Leukemia Risk Due to an IKZF1 Noncoding Regulatory Variant
4899 - Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis
4943 - Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
4003 - Racial and Ethnic Disparities in Childhood Acute Lymphoblastic Leukemia Risk Due to an IKZF1 Noncoding Regulatory Variant
4899 - Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis
4943 - Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib
Ma, X.
436 - Subtype Dependent Drug Resistance Alterations in Relapsed Childhood B-ALL: A Children’s Oncology Group Study
1467 - Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
2801 - Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
3906 - Tracking Clonal Evolution in Pediatric AML
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
1467 - Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
2801 - Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
3906 - Tracking Clonal Evolution in Pediatric AML
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
Ma, X.
34 - Predictors, Risk Factors and Outcomes of Patients with SAA with Anti-HLA Class I Antibodies Treated with Immunosuppressive Therapy
197 - The Role of Heterozygous Variants in SAMD9/9L and Recessive Bone Marrow Failure-Related Genes in Adults with Severe Aplastic Anemia
2541 - Clonal Hematopoiesis in Vexas Syndrome
2583 - Characterizing Immunodeficiency in Patients with Telomere Biology Disorders
197 - The Role of Heterozygous Variants in SAMD9/9L and Recessive Bone Marrow Failure-Related Genes in Adults with Severe Aplastic Anemia
2541 - Clonal Hematopoiesis in Vexas Syndrome
2583 - Characterizing Immunodeficiency in Patients with Telomere Biology Disorders
Ma, X.
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
1925 - MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
3243 - MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
1925 - MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
3243 - MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
Ma, Y.
Ma, Y.
Ma, Y.
Ma-Edmonds, M.
2859 - Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial
Maag, A. H.
Maahs, L.
Maakaron, J.
1618 - Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
4623 - A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML
4666 - Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
4623 - A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML
4666 - Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
Maakaron, J. E.
114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
657 - Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
2005 - Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
657 - Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
2005 - Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Maaziz, N.
Mabilleau, G.
Macari, E. R.
Macaron, W.
213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
224 - Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
224 - Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
Macaulay, C.
322 - MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
Macauley, I.
Maccaferri, M.
Maccari, C.
Macchi, S.
MacDonald, B.
2339 - DISC-0974, an Anti-Hemojuvelin Antibody, Reduces Hepcidin and Mobilizes Iron in Healthy Volunteers
2346 - Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria: Beacon Trial Design
3641 - DISC-0974, an Anti-Hemojuvelin (HJV) Monoclonal Antibody, Reduced Hepcidin and Improved Anemia in a Rat Model of Chronic Kidney Disease
3661 - Bitopertin, a Selective Glycine Transporter 1 Inhibitor, Reduced Protoporphyrin IX (PPIX) Level and Improved Liver Fibrosis in a Mouse Model of Erythropoietic Protoporphyria (EPP)
2346 - Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria: Beacon Trial Design
3641 - DISC-0974, an Anti-Hemojuvelin (HJV) Monoclonal Antibody, Reduced Hepcidin and Improved Anemia in a Rat Model of Chronic Kidney Disease
3661 - Bitopertin, a Selective Glycine Transporter 1 Inhibitor, Reduced Protoporphyrin IX (PPIX) Level and Improved Liver Fibrosis in a Mouse Model of Erythropoietic Protoporphyria (EPP)
MacDonald, C. R.
MacDonald, D.
Macdougall, A.
MacDougall, A.
MacDougall, K.
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
4953 - Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology
4953 - Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology
Macé, S.
247 - Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
1923 - Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results
3176 - Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
1923 - Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results
3176 - Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
Machado, J. H.
Machado, P. P. F.
Machado-Neto, J. A.
Macher, N.
Machherndl-Spandl, S.
561 - Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine – a Prospective Cohort Study By the AGMT
832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
Machida, R.
Machiela, M.
373 - JAK2 V617F Mutation and Associated Chromosomal Alterations Involving JAK2 in Pre-HCT Blood Samples and Transplant Outcomes in Myelofibrosis Subtypes
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
Machin, N. C.
590 - Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease
3787 - Prevalence of Heavy Menstrual Bleeding and Use of Hormonal Therapy Among Women Type 1 Von Willebrand Disease from the Zimmerman Program
3787 - Prevalence of Heavy Menstrual Bleeding and Use of Hormonal Therapy Among Women Type 1 Von Willebrand Disease from the Zimmerman Program
Machlus, K.
Machogu, E.
Machura, A.
Maciag, P.
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
Macias, A.
Macias, I.
Maciejewski, J. P.
85 - Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies
120 - Chip–Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders
340 - TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis
507 - Splenectomy for Immune Cytopenias: Treatment Outcomes and Predictors of Response
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
823 - Demonstration That Loss of TET2 Impairs DNA Mismatch Repair Resulting in Clonally Restricted Genomic Instability
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1246 - New Approaches to Chronic Idiopathic Neutropenia in the Era of Clonal Hematopoiesis
1248 - Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria
1746 - ANKRD26 Coding Variants in Myeloid Neoplasia
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
2564 - Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Arising from Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
2565 - Immune Checkpoint Molecules Regulate Paroxysmal Nocturnal Hemoglobinuria Clonal Evolution
2567 - Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3062 - Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association
3064 - Splicing Analysis Unveils Convergent Transcriptomic Pathways in U2AF1 S34 and Q157 Mutant Myeloid Neoplasia
3087 - Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome
3158 - Heightened Endoplasmic-Reticulum Stress Is a Targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma
3818 - Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs
3883 - Deciphering Treatment Patterns in Non-Severe Aplastic Anemia: An International Observational Study
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
3917 - Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting
3955 - Role of MBD4 Mutation in Neoplastic Evolution of Acute Myeloid Leukemia
3969 - Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML
4123 - Clinical and Molecular Features of FTL3 non Canonical and Activation Loop Mutations
4231 - Clinical and Mechanistic Relationship of T-Cell Large Granular Lymphocytic Leukemia (TLGL) and monoclonal Gammopathy of Undetermined Significance (MGUS)
4379 - Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia
4762 - Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M
120 - Chip–Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders
340 - TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis
507 - Splenectomy for Immune Cytopenias: Treatment Outcomes and Predictors of Response
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
823 - Demonstration That Loss of TET2 Impairs DNA Mismatch Repair Resulting in Clonally Restricted Genomic Instability
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1246 - New Approaches to Chronic Idiopathic Neutropenia in the Era of Clonal Hematopoiesis
1248 - Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria
1746 - ANKRD26 Coding Variants in Myeloid Neoplasia
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
2564 - Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Arising from Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
2565 - Immune Checkpoint Molecules Regulate Paroxysmal Nocturnal Hemoglobinuria Clonal Evolution
2567 - Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3062 - Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association
3064 - Splicing Analysis Unveils Convergent Transcriptomic Pathways in U2AF1 S34 and Q157 Mutant Myeloid Neoplasia
3087 - Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome
3158 - Heightened Endoplasmic-Reticulum Stress Is a Targetable Vulnerability of Malignant Plasma Cells in Multiple Myeloma
3818 - Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs
3883 - Deciphering Treatment Patterns in Non-Severe Aplastic Anemia: An International Observational Study
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
3917 - Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting
3955 - Role of MBD4 Mutation in Neoplastic Evolution of Acute Myeloid Leukemia
3969 - Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML
4123 - Clinical and Molecular Features of FTL3 non Canonical and Activation Loop Mutations
4231 - Clinical and Mechanistic Relationship of T-Cell Large Granular Lymphocytic Leukemia (TLGL) and monoclonal Gammopathy of Undetermined Significance (MGUS)
4379 - Dead and Deah-Box Helicases Other Than DDX41 Are Mutated in Myeloid Neoplasia
4762 - Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M
Maciel, T. T.
Macintyre, E. A.
Maciocia, N. C.
Maciocia, P. M.
Mack, J. M.
Mack, J.
Mack, M.
Mack, T.
Mack, T. M.
Mackall, C. L.
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
982 - CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study
2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4662 - Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
982 - CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study
2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4662 - Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
Mackay, C.
Mackensen, A.
998 - Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
1350 - Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response
1987 - Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
1993 - CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients
2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd
2863 - Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity
3348 - Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL
4185 - Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis
4618 - Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy
1350 - Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response
1987 - Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
1993 - CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients
2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd
2863 - Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity
3348 - Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL
4185 - Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis
4618 - Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy
Mackenzie, B.
Mackey, J. R.
Mackler, E.
3552 - Strategies for Implementing an Oral Medication Adherence Intervention in Academic and Community Cancer Settings
4920 - Impact of Initiating Oral Anticancer Agent Therapy for Chronic Lymphocytic Leukemia Among Adults with Multiple Chronic Conditions
4949 - Impact of Initiating Oral Anticancer Agent Therapy for Chronic Myelogenous Leukemia Among Adults with Multiple Chronic Conditions
4920 - Impact of Initiating Oral Anticancer Agent Therapy for Chronic Lymphocytic Leukemia Among Adults with Multiple Chronic Conditions
4949 - Impact of Initiating Oral Anticancer Agent Therapy for Chronic Myelogenous Leukemia Among Adults with Multiple Chronic Conditions
Mackler, N. J.
Mackman, N.
5 - C1 Inhibitor Deficiency Results in Increased Activation of Coagulation and Enhanced Venous Thrombosis
2437 - Decreased Platelet Reactivity and Function in a Mouse Model of Pancreatic Cancer
3754 - Thrombocytopenia in a Mouse Model of Pancreatic Cancer
3759 - Tissue Factor (TF) Is Upregulated in Tumor-Bearing Mice Treated with Immune Checkpoint Inhibitor (ICI)
2437 - Decreased Platelet Reactivity and Function in a Mouse Model of Pancreatic Cancer
3754 - Thrombocytopenia in a Mouse Model of Pancreatic Cancer
3759 - Tissue Factor (TF) Is Upregulated in Tumor-Bearing Mice Treated with Immune Checkpoint Inhibitor (ICI)
Maclachlan, K. H.
100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
638 - Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma
643 - Tracking the Earliest Genomic Events in Multiple Myeloma Life-History
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
992 - Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3170 - The Mutagenic Impact of Radiotherapy in Multiple Myeloma
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
4489 - Geometric Network Analysis Defines Poor-Prognosis Subtypes in Multiple Myeloma
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
638 - Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma
643 - Tracking the Earliest Genomic Events in Multiple Myeloma Life-History
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
992 - Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3170 - The Mutagenic Impact of Radiotherapy in Multiple Myeloma
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
4489 - Geometric Network Analysis Defines Poor-Prognosis Subtypes in Multiple Myeloma
MacLaren Ehui, L.
MacLean, N.
1289 - Intracellular IL-23 Receptor (IL-23R) Is Necessary for AML Viability and Regulates Mitotic Spindle and Centrosome Formation
3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors
3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors
MacLeod, R.
MacMillan, M. L.
113 - Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis
114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
2237 - Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis
4708 - Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes
114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
2237 - Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis
4708 - Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes
MacPhee, L.
Macpherson, M. D.
MacRae, T.
Macrae, T.
Macro, M.
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
1880 - Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
3245 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
1880 - Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
3245 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
MacWhirter - DiRaimo, J.
1138 - COVID-19 Vaccination in Children and Young Adults with Pre-Existing Immune Thrombocytopenia (ITP): Preliminary Data from the Platelet Disorder Support Association (PDSA) Patient Registry
2448 - Does IVIG Use Reduce the Risk of Contracting Sars-Cov-2 in Patients with Immune Thrombocytopenia: Data from the Platelet Disorder Support Association (PDSA) Patient Registry
2448 - Does IVIG Use Reduce the Risk of Contracting Sars-Cov-2 in Patients with Immune Thrombocytopenia: Data from the Platelet Disorder Support Association (PDSA) Patient Registry
Madan, K.
Madan, S.
1923 - Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma
Madanat, Y. F.
459 - Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1383 - Racial and Ethnic Disparities in Acute Myeloid Leukemia: 15-Year Experience at a Safety-Net Health System
2072 - Post-Transplant Cyclophosphamide Associated with Increased Early Mixed Donor Chimerism in Myeloid Malignancies; A Single-Center Experience
2273 - Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?
2279 - Do Monoclonal Antibody Therapies Improve ‘Real-World’ Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
2760 - Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3603 - Real World Patient Reported Outcomes Evaluating the Impact of Hematologic Malignancies on Patient Quality of Life
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
4091 - A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1383 - Racial and Ethnic Disparities in Acute Myeloid Leukemia: 15-Year Experience at a Safety-Net Health System
2072 - Post-Transplant Cyclophosphamide Associated with Increased Early Mixed Donor Chimerism in Myeloid Malignancies; A Single-Center Experience
2273 - Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?
2279 - Do Monoclonal Antibody Therapies Improve ‘Real-World’ Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
2760 - Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3603 - Real World Patient Reported Outcomes Evaluating the Impact of Hematologic Malignancies on Patient Quality of Life
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
4091 - A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
Madarang, E.
Maddaloni, D.
Maddams, R.
Madden, R. M.
Maddocks, K. J.
73 - Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma
77 - Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
323 - Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2884 - Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis
2897 - Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry
2937 - L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
2963 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
- Moderator Introduction
77 - Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
323 - Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2884 - Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis
2897 - Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry
2937 - L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
2963 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
- Moderator Introduction
Madduri, D.
1884 - Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1
2023 - DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
2030 - Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
3354 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
2023 - DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
2030 - Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
3354 - Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
Madeira, M. I. A.
Mader, M.
852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)
Madera, A.
Madigan, K.
63 - The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
Madireddy, A.
Madison, B.
Madison, S. D.
Madni, M.
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
Madry, K.
Madsen, C.
Maeda, D. Y.
Maeda, L. S.
Maeda, T.
Maeda, T.
Maeda, Y.
1427 - Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
2858 - Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan
4579 - Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
2858 - Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan
4579 - Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
Maegawa, R.
3014 - Population Pharmacokinetics in Hepatic and Renal Impairment and PBPK Drug-Drug Interaction Simulations of Asciminib, a Novel Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia in Chronic Phase
3023 - Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation
3023 - Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation
Maerevoet, M.
956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
2948 - Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study
2948 - Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study
Maertens, J.
371 - Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
988 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation
4680 - Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
988 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation
4680 - Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
Maertens, J. A.
55 - Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial
302 - Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party
838 - Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
4110 - Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
302 - Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party
838 - Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
4110 - Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
Maes, A.
Maes, A.
Maes, P.
Maestrali, M.
Maettler, C. T.
Maetzig, T.
Maffioli, M.
Maffucci, C.
Magagnoli, M.
2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study
4261 - Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors
4261 - Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors
Magalhaes, E. S.
Magalhaes-Silverman, M.
Maganti, H. B.
Maganti, M.
Magaziner, S. J.
Magee, A. S.
Magee, J. A.
1214 - BCLAF1 Regulates Expression of AP-1 Genes and Fetal Hematopoietic Stem Cell Repopulation Activity
1954 - KMT2C/MLL3 Attenuates Committed Myeloid Progenitor Self-Renewal Capacity and Balances Granulocyte and Monocyte/Dendritic Cell Output
2595 - FLT3-ITD Drives Context-Specific Changes in Cell Identity and Variable Interferon Dependence during AML Initiation
2607 - A Stress Response Pathway That Enhances Hematopoietic Stem Cell Longevity Promotes Acute Myeloid Leukemia Growth and Progression
2616 - SKIDA1 Selectively Sustains MLL-ENL-Expressing Hematopoietic Stem and Progenitor Cells
1954 - KMT2C/MLL3 Attenuates Committed Myeloid Progenitor Self-Renewal Capacity and Balances Granulocyte and Monocyte/Dendritic Cell Output
2595 - FLT3-ITD Drives Context-Specific Changes in Cell Identity and Variable Interferon Dependence during AML Initiation
2607 - A Stress Response Pathway That Enhances Hematopoietic Stem Cell Longevity Promotes Acute Myeloid Leukemia Growth and Progression
2616 - SKIDA1 Selectively Sustains MLL-ENL-Expressing Hematopoietic Stem and Progenitor Cells
Magerus, A.
Maggio, A.
1034 - Chronic Hepatitis C Virus Infection Is Associated with an Increased Risk of Diabetes Mellitus in Thalassemia Major
1035 - Association between Myocardial Iron Overload and Diffuse Myocardial Fibrosis in Thalassemia Major
2354 - Cardiac Magnetic Resonance Predicts Heart Failure Mortality in Patients with Thalassemia Major
2355 - Link between Bone Marrow and Cardiac Iron Overload in Thalassemia Major
1035 - Association between Myocardial Iron Overload and Diffuse Myocardial Fibrosis in Thalassemia Major
2354 - Cardiac Magnetic Resonance Predicts Heart Failure Mortality in Patients with Thalassemia Major
2355 - Link between Bone Marrow and Cardiac Iron Overload in Thalassemia Major
Maggioni, A. P.
Maggioni, G.
464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
1741 - Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
4376 - A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region
1741 - Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
4376 - A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region
Magliacane, G.
Magnani, C. F.
1996 - Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
4644 - Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response
4644 - Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response
Magnotti, J.
Magnuson, B.
Magor, G. W.
283 - KLF1 Acts As a Pioneer Transcription Factor Via SMARCA4 to Open Chromatin and Facilitate Redeployment of an Enhancer Complex Containing GATA1 and SCL
454 - Germline Missense Variants in SH2B3 Underpin Platelet Count Variation and Inherited MPN
513 - Novel Immediate Direct Targets of EPO Signalling in Human Erythropoiesis
454 - Germline Missense Variants in SH2B3 Underpin Platelet Count Variation and Inherited MPN
513 - Novel Immediate Direct Targets of EPO Signalling in Human Erythropoiesis
Magpantay, L.
Magro, E.
Maguire, J. A.
Maguire, J. L.
Mahabhashyam, S.
Mahadevan, D.
Mahajan, A.
Mahajerin, A.
30 - Clinical and Treatment Characteristics of Infants and Toddlers Less Than Two Years of Age with Hemophilia: A Report from the Community Counts Registry
2490 - Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)
2490 - Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)
Mahajna, R.
Mahanti, H.
Mahar, R.
Maharaj, K.
Mahasneh, I.
Mahato, R. I.
Mahé, B.
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
3124 - Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53
3299 - Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
3124 - Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53
3299 - Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients
Mahendra-Rajah, S.
Mahendran, M.
Maher, K.
1734 - A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis
2314 - Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML
2817 - IDH1/2mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML
2314 - Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML
2817 - IDH1/2mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML
Mahevas, M.
23 - Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
Mahillo-Fernández, I.
Mahlangu, J.
Mahlangu, J.
Mahlich, J.
Mahmood, K.
3964 - Targeting Serine Biosynthesis in Combination with the Modulation of Glutamine Metabolism Enhances Cellular Cytotoxicity in Acute Myeloid Leukemia
3968 - Comprehensive Plasma Amino Acid Analysis Following Administration of Short- and Long-Acting Erwinia Asparaginase (Crisantaspase) Demonstrated Significant Increase in Plasma Serine and Glycine Levels
3968 - Comprehensive Plasma Amino Acid Analysis Following Administration of Short- and Long-Acting Erwinia Asparaginase (Crisantaspase) Demonstrated Significant Increase in Plasma Serine and Glycine Levels
Mahmood, O.
Mahmood, S.
Mahmoud, A. M.
Mahmoud, A.
Mahmoud Hourani Soutari, N.
Mahmoud, M. S.
Mahmoudjafari, Z.
1862 - Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naïve in Penta-Relapsed Refractory Multiple Myeloma (RRMM)
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
3187 - Daratumumab,Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients
3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
Mahmud, N.
2071 - G-CSF Improves Stable Engraftment in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Hematopoietic Stem Cell Transplantation
2651 - Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML
2651 - Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML
Mahon, B.
Mahoney, C.
Mahvish, T.
Mai, E. K.
644 - Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients – Meta-Analysis of 5,808 Trial Patients
860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
Mai, V.
Mai-Hong, W.
Maïer, B.
Maier, C. L.
Maierhofer, A.
Maiese, D.
Maifredi, S.
Maïga, S.
Maihemaiti, A.
Mailand, D.
Mailankody, S.
100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
251 - Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
992 - Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
4639 - A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC‑Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma
251 - Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
992 - Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
4639 - A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC‑Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma
Maillard, I.
426 - Real World Effectiveness of “7 + 3” Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia
1547 - A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders
3261 - Graft-Versus-Host Disease Induces Immune Dysregulation through Irreversible Damage to Specialized Immune-Interacting Fibroblastic Stromal Cells in Secondary Lymphoid Organs
3276 - Fibroblastic Stromal Cells Expressing Delta-like Notch Ligands Control Extrathymic T Cell Development in Mesenteric Lymph Nodes
4862 - Fried’s Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
1547 - A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders
3261 - Graft-Versus-Host Disease Induces Immune Dysregulation through Irreversible Damage to Specialized Immune-Interacting Fibroblastic Stromal Cells in Secondary Lymphoid Organs
3276 - Fibroblastic Stromal Cells Expressing Delta-like Notch Ligands Control Extrathymic T Cell Development in Mesenteric Lymph Nodes
4862 - Fried’s Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Maimaris, J.
Maiques-Diaz, A.
Maiques-Diaz, A.
Maira, D.
Maisano, D.
Maissenhaelter, B.
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
Maiti, A.
61 - Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
199 - C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
224 - Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
596 - Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
1337 - Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses
1432 - Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials
1441 - Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
1448 - Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
1689 - A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
4074 - Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
199 - C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
224 - Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
596 - Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
1337 - Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses
1432 - Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials
1441 - Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
1448 - Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
1689 - A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
4074 - Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
Maitland, S. A.
Maity, A.
Maity, R.
101 - Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)
864 - Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma
4476 - CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients
4793 - Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma
864 - Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma
4476 - CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients
4793 - Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma
Majchrzak, A.
Majeed, A.
Majeti, R.
Majhail, N. S.
369 - Late Graft Failure in MDS and Acute Leukemia Patients Receiving Allogenic Hematopoietic Cell Transplantation with Post Transplant Cyclophosphamide As Gvhd Prophylaxis
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study
Majluf-Cruz, A. S.
Major, A.
Major, A.
171 - Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
870 - Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)
- Entrepreneurship
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
870 - Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)
- Entrepreneurship
Majumdar, M.
Majumdar, S.
Majumdar, S.
Majumder, R.
Majzner, R. G.
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
Mak, D.
Mak, P. Y.
199 - C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas
1320 - Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3-ITD/-TKD Mutant AML in a PDX Model
2638 - Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML
3956 - Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia
1320 - Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3-ITD/-TKD Mutant AML in a PDX Model
2638 - Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML
3956 - Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia
Mak, T. W.
Makar, R. S.
Makaryan, V.
Makhaldiani, L.
Makhani, S. S.
2259 - Inpatient Burden and Clinical Outcomes of Febrile Neutropenia in Cancer Patients: A National Inpatient Sample Database Analysis
3604 - Impact of Sociodemographic and Socioeconomic Factors on Diffuse Large B-Cell Lymphoma (DLBCL)-Specific Mortality in the United States – a SEER PLUS Database Analysis Spanning 20 Years
3606 - Association of Socioeconomic and Sociodemographic Determinants on Mortality in Hodgkin’s Lymphoma in United States: A 20 Year SEER PLUS Retrospective Analysis
3604 - Impact of Sociodemographic and Socioeconomic Factors on Diffuse Large B-Cell Lymphoma (DLBCL)-Specific Mortality in the United States – a SEER PLUS Database Analysis Spanning 20 Years
3606 - Association of Socioeconomic and Sociodemographic Determinants on Mortality in Hodgkin’s Lymphoma in United States: A 20 Year SEER PLUS Retrospective Analysis
Makheja, M.
Makinde, A. Y.
389 - Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns
4412 - Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes
4412 - Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes
Makishima, H.
85 - Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies
202 - CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms
1228 - Distinct Pathogenesis of Clonal Hematopoiesis Revealed By Single Cell RNA Sequencing Integrated with Highly Sensitive Genotyping Method
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
2542 - Detailed Analysis of the Impact of Clonal Hematopoiesis on the Risk of Severe COVID-19 Infection
3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
202 - CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms
1228 - Distinct Pathogenesis of Clonal Hematopoiesis Revealed By Single Cell RNA Sequencing Integrated with Highly Sensitive Genotyping Method
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
2542 - Detailed Analysis of the Impact of Clonal Hematopoiesis on the Risk of Severe COVID-19 Infection
3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
Makiyama, J.
Makkuni, S.
Makruasi, N.
Maksakova, I.
Makubi, A. N.
Malagola, M.
Malandrakis, P.
647 - Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3221 - The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3221 - The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
Malaney, P.
Malard, F.
112 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
2068 - Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party
2765 - Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial
4718 - Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
2068 - Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party
2765 - Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial
4718 - Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation
Malarikova, D.
2671 - Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma
2840 - BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo
2852 - Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy
2840 - BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo
2852 - Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy
Malarkannan, S.
Malato, A.
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
Malay, S.
Malcolm, K. E.
Malcolmson, C.
Malcolmson, J.
Malcovati, L.
85 - Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies
86 - Clonal Trajectories and Therapeutic Targeting of High-Risk SF3B1-Mutant Myelodysplastic Syndromes
926 - Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
1005 - Silk Bone Marrow-like Niches for Red Cell Production Ex Vivo
1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
3038 - Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
3100 - Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4405 - Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
86 - Clonal Trajectories and Therapeutic Targeting of High-Risk SF3B1-Mutant Myelodysplastic Syndromes
926 - Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
1005 - Silk Bone Marrow-like Niches for Red Cell Production Ex Vivo
1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
3038 - Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
3100 - Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4405 - Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
Maldeney, A. R.
Maldonado, A.
Maldonado-Schmidt, S.
Male, C.
1136 - Identification By Longread Nanopore Sequencing of a Complex Structural Variant in ITGB3 with a Founder Effect Causing Glanzmann's Thrombasthenia in Two Unrelated Patients
1154 - The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results
1154 - The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results
Malec, L.
28 - U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics
590 - Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease
590 - Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease
Malech, H. L.
2408 - Extended Detection in Peripheral Blood Following Infusion of Chronic Granulomatous Disease Patient Autologous Granulocytes Corrected By mRNA Transfection in Patients with Chronic Granulomatous Disease
3456 - Highly Efficient & Specific Repair of MAGT1 Mutation in Xmen Patient T Cells and Hematopoietic Stem Cells
3456 - Highly Efficient & Specific Repair of MAGT1 Mutation in Xmen Patient T Cells and Hematopoietic Stem Cells
Malecka, A.
Małecka-Giełdowska, M.
Małecki, J. M.
Malek, E.
778 - Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
1876 - Proteasome Regulatory Atpases PSMC2 and PSMC6 Modulate Proteosome Inhibitor Sensitivity and Correlate with Survival in Multiple Myeloma
2176 - A Tool to Longitudinally Assess the Secretory Capacity of Myeloma Cells throughout the Course of Disease
3224 - African American Race Is a Potential Favorable Biologic Factor That Impacts Clinical Outcome for Patients with Multiple Myeloma
3502 - Artificial Intelligence to Assess the Systemic Impact of Malignant Plasma Cell Clone in Patients with Plasma Cell Dyscrasia
4858 - Early Onset of Smoldering Disease Correlates with Rapid Progression to Symptomatic Multiple Myeloma
1876 - Proteasome Regulatory Atpases PSMC2 and PSMC6 Modulate Proteosome Inhibitor Sensitivity and Correlate with Survival in Multiple Myeloma
2176 - A Tool to Longitudinally Assess the Secretory Capacity of Myeloma Cells throughout the Course of Disease
3224 - African American Race Is a Potential Favorable Biologic Factor That Impacts Clinical Outcome for Patients with Multiple Myeloma
3502 - Artificial Intelligence to Assess the Systemic Impact of Malignant Plasma Cell Clone in Patients with Plasma Cell Dyscrasia
4858 - Early Onset of Smoldering Disease Correlates with Rapid Progression to Symptomatic Multiple Myeloma
Malenica, I.
Malerba, L.
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
Malfona, F.
Malfona, F.
Malhamé, I.
Malhan, H.
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Malhotra, P.
Malhotra, S.
Malighetti, F.
Malik, A.
21 - Do Children with Immune Thrombocytopenia Have Cerebral Microbleeds?
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
Malik, A.
Malik, M.
Malik, P.
Malik, S. A.
Malila, N.
4209 - Survival, Transformation and Causes of Death of Follicular Lymphoma: A Finnish Nationwide Population-Based Study
4249 - Subsequent Malignant Neoplasms after Primary Hematological Malignancy in Adult Patients (Aged ≥20 Years) – High Risk of Hodgkin Lymphoma in Patients with Chronic Lymphocytic Leukemia
4249 - Subsequent Malignant Neoplasms after Primary Hematological Malignancy in Adult Patients (Aged ≥20 Years) – High Risk of Hodgkin Lymphoma in Patients with Chronic Lymphocytic Leukemia
Malinowski, A. K.
139 - LEAP Pilot: Low Molecular Weight Heparin Vs. Aspirin Postpartum
806 - Sickle Cell Disease-Specific Blood Pressure Thresholds for Hypertensive Disorders of Pregnancy: A Multinational Study
1079 - Pregnancy Outcomes and Iron Status in the Context of Beta Thalassemia Major and Intermedia: A Systematic Review and Meta-Analysis
3716 - Trajectory of Blood Pressure in Pregnant People with Sickle Cell Disease: A Multinational Study
806 - Sickle Cell Disease-Specific Blood Pressure Thresholds for Hypertensive Disorders of Pregnancy: A Multinational Study
1079 - Pregnancy Outcomes and Iron Status in the Context of Beta Thalassemia Major and Intermedia: A Systematic Review and Meta-Analysis
3716 - Trajectory of Blood Pressure in Pregnant People with Sickle Cell Disease: A Multinational Study
Maliske, S. M.
Malkan, U. Y.
Malladi, R.
Mallari, C. R.
Mallegni, F.
Maller, O.
Mallick, R.
Mallikarjunan, A.
Mallm, J. P.
860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML
4487 - Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma
3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML
4487 - Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma
Mallo, M.
2177 - Pilot Inter-Laboratory Comparison Study of Optical Genome Mapping Analysis for Cytogenomic Characterization of Hematological Malignancies: A Spanish Multicentric Study
2822 - IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
2822 - IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial
Mallouri, D.
Malloy, S.
Mallya, P.
3330 - Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)
4646 - Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)
4646 - Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)
Malmberg, A.
Malmberg, K. J.
Malmros, J.
Maloisel, F.
Malone, A.
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
Malone, K.
Maloney, D. G.
3316 - Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
4654 - CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study
4660 - 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
4654 - CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study
4660 - 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Maloney, D. G.
Maloney, K. W.
Malouf, C.
Malovannaya, A.
Malpica Castillo, L. E.
Malpica Castillo, L. E.
445 - Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions
1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
1615 - Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin
2965 - Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis
2980 - Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
2985 - Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
4233 - Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response
4676 - Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy
4905 - Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
1615 - Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin
2965 - Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis
2980 - Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
2985 - Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
4233 - Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response
4676 - Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy
4905 - Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Malsch, M.
Malukhina, K.
Maluquer, C.
Maly, J. J.
854 - Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
4555 - Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
4555 - Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
Malyarenko, D.
Mamidipalli, A.
Mammadzadeh, A.
Mamonkin, M.
Mamot, C.
735 - Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
2959 - Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)
2959 - Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)
Mamouni, K.
Man, C. H.
Man, N.
Man, Y.
Manafas, A.
Manalis, S. R.
Manalo, J.
Manara, P.
3483 - The Marine Product Elatol Is a Novel Inhibitor of Mitochondrial Translation Triggering the Integrated Stress Response and Apoptosis in Leukemia and Lymphoma Cells
3986 - Translatome Reprogramming By Rocaglates in Lymphoma Induces Drug Resistance through up-Regulation of CD98hc, Activating Downstream AKT Survival Signaling
3986 - Translatome Reprogramming By Rocaglates in Lymphoma Induces Drug Resistance through up-Regulation of CD98hc, Activating Downstream AKT Survival Signaling
Manasanch, E. E.
Manasanch, E. E.
1929 - Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis
3169 - Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment
4914 - Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
3169 - Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment
4914 - Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
Manavalan, J. S.
3988 - The Novel Nano-Formulation of the HDAC Inhibitor, Romidepsin, for the Treatment of Relapsed, Refractory Peripheral T-Cell Lymphoma
4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
Manca, A.
Manceau, S.
Manceau, S.
Mancebo, C.
Mancini, V.
4048 - BCL-2 and BCL-XL Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study
4079 - Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results
4079 - Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results
Manco-Johnson, M. J.
Mancuso, G.
Mancuso, M. E.
187 - Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
Mancuso, N.
Manda, S.
Mandac Smoljanovic, I.
Mandal, K.
Mandala, E.
Mandava, M.
Mandefro, B.
Mandelboim, M.
Manders, F.
Mandeville, T.
Mandhair, H.
Mañe-Pujol, J.
Maneechai, K.
Maneikis, K.
Manes, N.
Manesia, J.
Maness, L.
573 - Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
4054 - Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients' Function and Health-Related Quality of Life Change with Treatment?
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
4054 - Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients' Function and Health-Related Quality of Life Change with Treatment?
Manfra, I.
Manfredini, R.
Mangalaparthi, K.
Mangalmurti, N. S.
Mangaonkar, A. A.
537 - Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
1233 - Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
2121 - IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
2541 - Clonal Hematopoiesis in Vexas Syndrome
3074 - Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
3899 - Longitudinal Single Cell Multiomic Analysis of a Patient with GATA2 Haploinsufficiency with ASXL1 Mutant Clonal Hematopoiesis
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
1233 - Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
2121 - IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort
2541 - Clonal Hematopoiesis in Vexas Syndrome
3074 - Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
3899 - Longitudinal Single Cell Multiomic Analysis of a Patient with GATA2 Haploinsufficiency with ASXL1 Mutant Clonal Hematopoiesis
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Mangelberger-Eberl, D.
Mangiacavalli, S.
Mangiavacchi, J.
Mangolini, M.
Mangukia, N.
Mangus, H.
Mani, D.
Mani, S.
Mani, T.
Mani, T.
Manier, S.
159 - Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1936 - Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1936 - Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
Manieri, M. V.
Manieri, V. M.
Manika, I.
Manikoth Ayyathan, D.
Manis, J. P.
32 - Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated Immunosuppression
2525 - Altered Cellular Sedimentation during Apheresis Impacts Outcomes of Peripheral Blood Stem Cell Collection Efficiency in Patients with Sickle Cell Disease
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
4786 - Therapeutic Gene Editing of HSCs Ex Vivo without in Vitro Culture Avoids Genotoxicity, Simplifies Procedures, and Preserves Efficiency and Stemness
2525 - Altered Cellular Sedimentation during Apheresis Impacts Outcomes of Peripheral Blood Stem Cell Collection Efficiency in Patients with Sickle Cell Disease
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
4786 - Therapeutic Gene Editing of HSCs Ex Vivo without in Vitro Culture Avoids Genotoxicity, Simplifies Procedures, and Preserves Efficiency and Stemness
Manis, J. P.
Manischewitz, J.
Maniusyte, R.
2047 - Prevalence of Sars-Cov-2 in Stem Cell Donors from Anthony Nolan UK Stem Cell Registry: Sars-Cov-2 Testing Programme, Impact on Stem Cell Collections and Managing Risk Going Forward
3361 - Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes
3361 - Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes
Manjelievskaia, J.
Mankel, B.
Manley, A. L.
193 - JAK 1/2 Inhibition Preserves Hematopoietic Progenitor and Stem Cells, Prevents Aplasia, Inhibits Pro-Inflammatory Cytokines, and Prolongs Survival in Murine Immune Bone Marrow Failure
2563 - Ruxolitinib Stimulates Expansion of Regulatory T Cells in Murine Immune Bone Marrow Failure
4874 - Alemtuzumab and Eltrombopag Combination for Patients with Refractory or Relapsed Severe Aplastic Anemia
2563 - Ruxolitinib Stimulates Expansion of Regulatory T Cells in Murine Immune Bone Marrow Failure
4874 - Alemtuzumab and Eltrombopag Combination for Patients with Refractory or Relapsed Severe Aplastic Anemia
Mann, K. K.
Mann, M.
Manna, A.
Mannarelli, C.
744 - Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
1720 - Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis
3042 - Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)
4060 - Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
4367 - Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency ≤1%
1720 - Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis
3042 - Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)
4060 - Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
4367 - Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency ≤1%
Manne, B. K.
Mannelli, F.
342 - Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
741 - JAK2V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis
3042 - Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)
4060 - Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
4367 - Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency ≤1%
741 - JAK2V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis
3042 - Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)
4060 - Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
4367 - Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency ≤1%
Manner, K.
Mannering, N.
Mannherz, W.
Manni, M.
613 - Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network
4286 - The Dramatic Impact of the War on Access to Treatment for Lymphoma Patients. a Report from the Ukrainian Lymphoma Registry
4286 - The Dramatic Impact of the War on Access to Treatment for Lymphoma Patients. a Report from the Ukrainian Lymphoma Registry
Mannina, D.
Mannina, D.
751 - Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
2886 - Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial
2886 - Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial
Manning, B.
Manning, M.
4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
Mannino, K.
Mannis, G. N.
1429 - Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis
1436 - V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type
1462 - Measurable Residual Disease Conversion Rate with Consolidation Chemotherapy in Acute Myeloid Leukemia
1436 - V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type
1462 - Measurable Residual Disease Conversion Rate with Consolidation Chemotherapy in Acute Myeloid Leukemia
Mannisto, S.
Manochakian, R.
Manolova, V.
Manousou, K.
3244 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
4569 - Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)
4569 - Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)
Manousou, K.
761 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
Manrique, I.
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
868 - Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
868 - Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
Manriquez-Roman, C.
256 - Targeting a Dominant Negative Splice Variant of TRAIL to Enhance CART Cell Functions
654 - Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models
977 - CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy
1981 - Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial
3862 - Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling
4610 - Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19
654 - Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models
977 - CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy
1981 - Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial
3862 - Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling
4610 - Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19
Mansfield, C.
Mansilla-Soto, J.
Manske, M. K.
18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
3720 - An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
3720 - An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
Mansour, D.
Mansour, J.
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
Mansour, M. R.
420 - IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions
715 - The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
1311 - The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL
1977 - Pharmacological Modulation of CD21 Antigen Density Enhances Chimeric Antigen Receptor (CAR-T) Cell Function
715 - The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
1311 - The Hematopoietic Transcription Factor GATA3 Is the Main Activator of Enhancer-Mediated Activation of Oncogenic TAL1 in T-ALL
1977 - Pharmacological Modulation of CD21 Antigen Density Enhances Chimeric Antigen Receptor (CAR-T) Cell Function
Mansour, M.
Mansour, R. P.
1067 - Incidence of VTE in Pregnant Women with Sickle Cell Gene Mutation(s): A Retrospective Database Analysis
3520 - Evaluation of the Efficacy of Flow-Cytometry in the Work-up of Leukopenia: An Institutional Retrospective Analysis
4881 - Outcomes in Pregnant HbSS and HbSβ0-Thalassemia Sickle Cell Disease Patients Receiving Scheduled Exchange Transfusions: A Retrospective Study
3520 - Evaluation of the Efficacy of Flow-Cytometry in the Work-up of Leukopenia: An Institutional Retrospective Analysis
4881 - Outcomes in Pregnant HbSS and HbSβ0-Thalassemia Sickle Cell Disease Patients Receiving Scheduled Exchange Transfusions: A Retrospective Study
Mansour-Hendili, L.
Mansukhani, M. M.
4515 - Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients
Mantalaris, A.
Manteigas, D.
Mantell, M. R.
Mantzaris, I.
268 - Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
1455 - Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay
2766 - A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort
2783 - Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia
3065 - Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML
3541 - Trends in Collection and Utilization of Autologous Hematopoietic Stem Cells (APBHC) Intended for Transplant in Patients with Multiple Myeloma
4919 - Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis
4948 - Factors Associated with Early Mortality in Patients with Multiple Myeloma: A SEER Analysis
1455 - Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay
2766 - A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort
2783 - Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia
3065 - Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML
3541 - Trends in Collection and Utilization of Autologous Hematopoietic Stem Cells (APBHC) Intended for Transplant in Patients with Multiple Myeloma
4919 - Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis
4948 - Factors Associated with Early Mortality in Patients with Multiple Myeloma: A SEER Analysis
Mantzou, A.
1031 - Evidence That Platelets from Transfusion-Dependent Thalassemia Patients Induce T Cell Activation
3690 - The Clinical Significance of the Glomerular Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) in Renal Function of Caucasian Patients with Compound Heterozygosity for Hb S and β-Thalassemia
3801 - Evaluation of Wnt/β-Catenin Pathway Circulating Proteins in Children and Adolescents with Hemophilia: Correlation with the Degree of Hemophilic Arhtropathy
3690 - The Clinical Significance of the Glomerular Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) in Renal Function of Caucasian Patients with Compound Heterozygosity for Hb S and β-Thalassemia
3801 - Evaluation of Wnt/β-Catenin Pathway Circulating Proteins in Children and Adolescents with Hemophilia: Correlation with the Degree of Hemophilic Arhtropathy
Manubens Guarch, A.
Manuel, M.
Manukonda, V. V.
Manwani, D.
178 - Dietary Iron Restriction Alters Microbiota-Host Crosstalk and Protects Against Vaso-Occlusion and Organ Damage in Sickle Cell Disease Mice
886 - Assessing Multi-Level Barriers to Medication Adherence in Youth with Sickle Cell Disease Using Pharmacy-Based Prescription Refill Data
1019 - Heme and Iron Aggravate Tissue Damage in Sickle Cell Disease By Driving Macrophage Functional Reprogramming through the Coordinated Suppression of Efferocytosis and Mitochondrial Metabolism
2375 - Active Study: Impact of Voxelotor on Sleep Quality, Physical Activity, and Patient-Reported Outcomes
2388 - Impact of MRA Echo Time on Stroke Prevention Therapy in Pediatric Patients with Sickle Cell Disease
3577 - Similar Patient-Reported Quality of Life in the US and UK in Patients with Sickle Cell: A Comparative Grndad/Cousin Study
886 - Assessing Multi-Level Barriers to Medication Adherence in Youth with Sickle Cell Disease Using Pharmacy-Based Prescription Refill Data
1019 - Heme and Iron Aggravate Tissue Damage in Sickle Cell Disease By Driving Macrophage Functional Reprogramming through the Coordinated Suppression of Efferocytosis and Mitochondrial Metabolism
2375 - Active Study: Impact of Voxelotor on Sleep Quality, Physical Activity, and Patient-Reported Outcomes
2388 - Impact of MRA Echo Time on Stroke Prevention Therapy in Pediatric Patients with Sickle Cell Disease
3577 - Similar Patient-Reported Quality of Life in the US and UK in Patients with Sickle Cell: A Comparative Grndad/Cousin Study
Manz, M. G.
55 - Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial
651 - Clonal Dynamics after Haematopoietic Stem Cell Transplantation Using Genome-Wide Somatic Mutations
838 - Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
3342 - CAR T Cells and Their Immune Environment Synergize to Shape Distinct Immune Profiles in Response Versus Toxicity in B Cell Lymphoma Patients
4110 - Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
651 - Clonal Dynamics after Haematopoietic Stem Cell Transplantation Using Genome-Wide Somatic Mutations
838 - Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
3342 - CAR T Cells and Their Immune Environment Synergize to Shape Distinct Immune Profiles in Response Versus Toxicity in B Cell Lymphoma Patients
4110 - Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
Manzano, J. G.
Manzoli, L.
Manzoni, D.
1777 - Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom
2793 - AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
2793 - AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
Manzoor, B. S.
Mao, C.
Mao, D.
Mao, M.
Mao, M.
Mao, S.
Mao, X.
Mapara, M. Y.
1838 - MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism
3267 - Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice
3582 - The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma
3267 - Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice
3582 - The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma
Mapara, M. Y.
11 - Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study
12 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease
2137 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
4459 - The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease
12 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease
2137 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
4459 - The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease
Maples, K. T.
Mar Fan, H.
Mara, C. A.
Mara, K. C.
Marabita, F.
Marafioti, T.
Marani, L. O.
Marano, L.
Marasca, R.
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
Marasco, V.
169 - Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial
2929 - Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage
2929 - Decisional Role of Interim PET in Relapsed/Refractory Classical Hodgkin Lymphoma Treated with Begev Chemotherapy As First Salvage
Marçais, A.
Marcault, C.
Marcellino, B. K.
60 - Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification
327 - Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis
1763 - Characterization of Myeloid Neoplasms in Inflammatory Bowel Disease
- PhD Careers
327 - Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis
1763 - Characterization of Myeloid Neoplasms in Inflammatory Bowel Disease
- PhD Careers
Marcello, A.
Marcello, L. T.
Marchal, C.
Marchand, T.
2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
Marchand, T.
Marchese, D.
Marchesini, M.
Marchetti, M.
1114 - Role of Hemostatic Biomarkers for the Identification of Patients with LONG-COVID19 Syndrome: Results from the ‘Accordi’ Study
1115 - Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
1118 - Inflammatory and Coagulation Biomarkers in Patients with Sars-COV2 Infection Receiving COVID-19 Convalescent Plasma: The Bergamo Registry
1115 - Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
1118 - Inflammatory and Coagulation Biomarkers in Patients with Sars-COV2 Infection Receiving COVID-19 Convalescent Plasma: The Bergamo Registry
Marchetti, M.
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
3131 - Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
3131 - Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
Marchetti, M.
2214 - Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines
3625 - Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study
3625 - Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study
Marchi, E.
3988 - The Novel Nano-Formulation of the HDAC Inhibitor, Romidepsin, for the Treatment of Relapsed, Refractory Peripheral T-Cell Lymphoma
4241 - A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma – a Bridge to Transplant and an Effective Salvage for the Unfit
4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
4931 - Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era
4241 - A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma – a Bridge to Transplant and an Effective Salvage for the Unfit
4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
4931 - Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era
Marchi, F.
Marchica, V.
1834 - Glutamate Metabolism Shapes Osteoclast Differentiation: New Potential Therapeutic Target to Block Osteoclastic Bone Resorption in Multiple Myeloma Patients
3005 - Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification
3005 - Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification
Marchione, D. M.
Marcinek, A.
Marcireau, C.
Marco, A.
Marco, C.
Marco De Lucas, F.
Marco-Vera, P.
Marcondes, M. Q.
3335 - A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
Marconi, G.
59 - The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2726 - Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation
4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2726 - Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation
4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
Marcos, A.
Marcos Jubilar, M.
Marcoux, N.
Marcucci, G.
40 - CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
149 - Homoharringtonine Exhibits Anti-Tumor Effect in T-Cell Acute Lymphoblastic Leukemia By Targeting Notch1/Myc Pathway
275 - Targeting SAMHD1 Promotes Anti-Tumor Immunity in Acute Myeloid Leukemia
415 - Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia
496 - Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
942 - Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed
1274 - TET2-Mediated mRNA and DNA Oxidation in Leukemia Homing and Immune Evasion
2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
2061 - Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2152 - Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity
2171 - Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS)
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
3382 - Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3909 - HDAC8 Disrupts DNA Damage Response By Deacetylation of U2AF1 in Inv(16) Acute Myeloid Leukemia
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
4787 - Targeting Leukemic Stem Cells in Acute Myeloid Leukemia Using a CpG-Linked Anti-Mir-126 Oligonucleotide
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
149 - Homoharringtonine Exhibits Anti-Tumor Effect in T-Cell Acute Lymphoblastic Leukemia By Targeting Notch1/Myc Pathway
275 - Targeting SAMHD1 Promotes Anti-Tumor Immunity in Acute Myeloid Leukemia
415 - Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia
496 - Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
772 - Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
942 - Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed
1274 - TET2-Mediated mRNA and DNA Oxidation in Leukemia Homing and Immune Evasion
2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
2061 - Pulmonary Engraftment Syndrome: A Unique Complication of Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2152 - Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity
2171 - Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS)
2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
3371 - Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS)
3374 - Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
3382 - Durable Leukemia and HIV Remission without Antiviral Therapy Following an Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) Using a Donor with CCR5-Δ32/Δ32 Homozygosity for an Acute Myeloid Leukemia (AML) Patient
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3909 - HDAC8 Disrupts DNA Damage Response By Deacetylation of U2AF1 in Inv(16) Acute Myeloid Leukemia
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity
4787 - Targeting Leukemic Stem Cells in Acute Myeloid Leukemia Using a CpG-Linked Anti-Mir-126 Oligonucleotide
Marcus, C. B.
Marcus, S.
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Margiotta Casaluci, G.
547 - Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi
4575 - Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion
4575 - Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion
Margolskee, E.
Margueron, R.
Margulies, S. L.
Marhelava, K.
Maria, G. D. S.
Mariani, S.
Mariano, J. L.
Mariano, L.
Mariano, R.
Marianovich, M.
Maric, D.
Maric, I.
Marien, A.
Mariette, C.
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
3212 - Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
3212 - Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study
Marijt, E. W.
950 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
2065 - Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3446 - Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
2065 - Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3446 - Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
Marin, D.
3422 - Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
Marin, J. F. G.
Marin Sanchez, A.
Marin-Bejar, O.
Marín-Mori, K.
Marin-Niebla, A.
Marín-Quílez, A.
Marinac, C. R.
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
- Nutrition Metabolism Connection (Epidemiologic Focus)
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
- Nutrition Metabolism Connection (Epidemiologic Focus)
Marinaccio, C.
Marinelli Busilacchi, E.
Marinez, M.
Marini, B. L.
Marini, F.
Marini, I.
Marini, O.
Marini, S.
Marinier, A.
Marino, F.
Marino, S.
Marinoni, M.
Marinovic, M. A.
Maris, M.
2760 - Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
3319 - ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
3319 - ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Mark, C.
Mark, K.
Markey, K. A.
Märkl, F.
Marklund, A.
Markovic, S. N.
Markovic, U.
Markovitz, D. M.
Markovitz, N. H.
Markovtsov, V. V.
Markowski, K.
Marks, D. I.
997 - Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
2684 - Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study
2684 - Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study
Marks, D. I.
Marks de Chabris, A.
Marks, L. J.
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
4301 - End of Treatment Positron Emission Tomography Response and Outcomes in Post-Transplant Lymphoproliferative Disorder
549 - Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas
4301 - End of Treatment Positron Emission Tomography Response and Outcomes in Post-Transplant Lymphoproliferative Disorder
Marks, R.
Marktel, S.
Markusic, D. M.
Marlton, P.
964 - Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
Marmor, Y.
Marneni, N.
Marneth, A. E.
452 - Mutant Srsf2 Diminishes Jak2V617F-Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2-Mutant MPN
4308 - Mutant Asxl1 Exacerbates the MPN Phenotype of Calrdel52 Mutant Mice with Distinct Effects on Histone H3 Modifications in Megakaryocytes
4308 - Mutant Asxl1 Exacerbates the MPN Phenotype of Calrdel52 Mutant Mice with Distinct Effects on Histone H3 Modifications in Megakaryocytes
Marolleau, J. P.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
1398 - Standard Risk-Assessment of AML Doesn’t Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy
4514 - Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study
1398 - Standard Risk-Assessment of AML Doesn’t Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy
4514 - Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study
Marone, R.
Marotta, S.
Marouf, A.
Marpakwar, R.
Marquart, H. V.
1505 - Single Cell Multi-Omic Profiling of Acute Lymphoblastic Leukemia Identifies Altered Cellular Pathways and Highlights Heterogeneity in the Maturation Block of DUX4-Rearranged ALL
1508 - Bone Marrow Plasma Proteome Analysis By Differential Ultracentrifugation and Tandem Mass Spectrometry Allow for Characterization of Leukemia-Derived Extracellular Vesicles in Patients with Acute Lymphoblastic Leukemia
1508 - Bone Marrow Plasma Proteome Analysis By Differential Ultracentrifugation and Tandem Mass Spectrometry Allow for Characterization of Leukemia-Derived Extracellular Vesicles in Patients with Acute Lymphoblastic Leukemia
Marques, F. D.
Marques, G.
Marques Ramos, P.
559 - Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
853 - Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
1770 - Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndrome (MDS)
853 - Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
1770 - Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndrome (MDS)
Marques-Piubelli, M. L.
550 - B-Cell Receptor Signaling Modulates Cholesterol Biosynthesis in Diffuse Large B-Cell Lymphoma
1562 - EOMES+ Tr1-like Cells Are Enriched in Areas of NLPHL Group II (Patterns D to F) Supporting the Role of Tregs in Disease Recurrence/Progression
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
1562 - EOMES+ Tr1-like Cells Are Enriched in Areas of NLPHL Group II (Patterns D to F) Supporting the Role of Tregs in Disease Recurrence/Progression
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
Marquet, J.
Marquet Palomanes, J.
320 - Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1707 - Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia
4448 - Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1707 - Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia
4448 - Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Marquez Almuina, N.
Marquez, M. E.
Marquez-Garcia, J.
Márquez-Malaver, F. J.
Marra, A.
Marra, M. A.
546 - Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
1518 - Towards a Unified Genetic Classification System for Diffuse Large B-Cell Lymphoma (DLBCL)
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
1518 - Towards a Unified Genetic Classification System for Diffuse Large B-Cell Lymphoma (DLBCL)
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
Marraffino, S.
Marrara, F.
Marrero, R. J.
432 - Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10
2800 - Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia
2800 - Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia
Marsal, J.
Marschner, I.
Marsh, J.
Marsh, R. A.
Marshall, A.
Marshall, A. L.
Marshall, K.
Marshall, L.
Marshall, S. R.
Marson, A.
Marszalek, J. R.
Marte, N.
Martelli, M. P.
879 - HLA-Matched Treg/Tcon Allogeneic Hematopoietic Cell Transplantation Is Safe and Ensures Remarkable Chronic GvHD/Leukemia Free Survival in High-Risk Leukemia Patients
4071 - A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure
4597 - Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia
4071 - A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure
4597 - Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia
Martelli, M. F.
Martelli, M.
710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
1549 - Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study
2214 - Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
3179 - Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience
4158 - Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients
4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial
1549 - Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study
2214 - Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
3179 - Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience
4158 - Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients
4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial
Martelli, M.
Martello, M.
Martens, E. S.
Martens, K. L.
Martens, M.
Martens, U. M.
Marth, G. T.
Marti, J. M.
99 - Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Martial, C.
Martial, M. A.
Martin, A. P.
577 - Health-Related Quality of Life, Disease Impacts, and Health Equity Concerns in Adults with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises: Preliminary Results from a Global Longitudinal Survey
4882 - Health-Related Quality of Life and Disease Impacts in Adults with Transfusion-Dependent β-Thalassemia: Preliminary Results from the Global Longitudinal Survey
4882 - Health-Related Quality of Life and Disease Impacts in Adults with Transfusion-Dependent β-Thalassemia: Preliminary Results from the Global Longitudinal Survey
Martin, A.
Martin, B.
Martin, B.
Martin Calvo, C.
Martin de Bustamante Gonzalez-Iglesias, J. M.
Martin De Fremont, G.
Martin, E.
Martin, E. M. D.
Martín García-Sancho, A.
155 - Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
320 - Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
4264 - Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma
4275 - Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group
320 - Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
4264 - Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma
4275 - Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group
Martin, G.
Martin, H.
1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site
Martin, J.
Martin, J. P.
Martin, J.
866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
Martin, K. A.
Martin Lopez, A. A.
155 - Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
658 - Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
658 - Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Martin, L.
Martin, M. R.
Martin, M. E.
Martin, M. E.
Martin Moro, F.
Martín Moro, F.
Martin, N.
868 - Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
869 - Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors
869 - Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors
Martin, O. Y.
Martin, P. J.
3258 - Lithium Attenuates Graft-Versus-Host Disease Via Effects on the Intestinal Stem Cell Niche
4591 - Targeting Intestinal Epithelial Ceacam1 Expands Peripheral Tregs and Prevents Steroid-Refractory Acute Gut Graft-Versus-Host Disease
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
4591 - Targeting Intestinal Epithelial Ceacam1 Expands Peripheral Tregs and Prevents Steroid-Refractory Acute Gut Graft-Versus-Host Disease
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
Martin, P. L.
Martin, P.
73 - Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma
77 - Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
205 - Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy
233 - Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
793 - Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
850 - Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1539 - Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
1567 - Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
2957 - Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium
4207 - Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group
4431 - Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up
4434 - Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
77 - Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
205 - Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy
233 - Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
793 - Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
850 - Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1539 - Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
1567 - Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
2957 - Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium
4207 - Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group
4431 - Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up
4434 - Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up
Martin, R. L.
Martín Salces, M.
1113 - Predictive Value of Platelet Sequestration Studies in Splenectomy Response
1127 - Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
3794 - Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
1127 - Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid
3794 - Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor
Martin, S.
Martin, S.
53 - Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
Martin, T.
250 - Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy
753 - Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis
1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
2030 - Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3176 - Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment
3218 - A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation
753 - Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis
1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
2030 - Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3176 - Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment
3218 - A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation
Martin, V.
Martin-Antonio, B.
3287 - Co-Transduced CD19/BCMA Dual-Targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma
4619 - Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma
4648 - CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
4619 - Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma
4648 - CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
Martín-Herrero, S.
Martin-Kool, B. A.
Martín-Muñoz, A.
Martín-Nuñez, G.
Martín-Quirós, A.
Martin-Ramos, M. L.
Martin-Regueira, P.
1682 - Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
4339 - Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
4339 - Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
Martín-Subero, J. I.
Martín-Subero, J. I.
725 - Whole-Genome Analysis of Histone Modifications Reveals New Insights into the Biology and Clinical Behavior of Mantle Cell Lymphoma Subtypes
745 - A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21R110
1795 - Development of a Novel Chromatin Activation Score As a Powerful Independent Prognostic Factor in Chronic Lymphocytic Leukemia
4424 - CRISPR-Cas9 Genome Editing of Primary Chronic Lymphocytic Leukemia Cells
745 - A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21R110
1795 - Development of a Novel Chromatin Activation Score As a Powerful Independent Prognostic Factor in Chronic Lymphocytic Leukemia
4424 - CRISPR-Cas9 Genome Editing of Primary Chronic Lymphocytic Leukemia Cells
Martindale, S. P.
1553 - Mechanistic Insights into Immune Related Toxicities in Subjects with Relapsed/ Refractory Follicular Lymphoma Treated with Zandelisib
3102 - Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib
3128 - Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia
4432 - Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter’s Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia
3102 - Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib
3128 - Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia
4432 - Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter’s Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia
Martinelli, G.
59 - The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
645 - A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies
710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2726 - Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation
4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
645 - A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies
710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2726 - Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation
4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
Martines, C.
Martinet, J.
Martinet, L.
Martinez, A.
Martínez, A.
Martinez Arias, A.
Martínez, A. L.
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Martinez Benitez, A. R.
330 - Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms (MPNs)
2992 - The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
2992 - The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
Martinez, C.
Martínez, C.
Martinez, C.
Martínez, C.
Martinez De Azcona Naharro, A.
Martínez de Miguel, B.
Martinez, E. Z.
Martinez Elicegui, J.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
Martínez Elicegui, J. M.
Martinez, E.
2615 - Fatty Acid Desaturation Is a Metabolic Vulnerability of Acute Myeloid Leukemia Cells
2997 - ERK2 Substrate Binding Domains Play Distinct Roles in Megakaryocytic-Erythroid Lineage Progression and Mediates Clonal Fitness in Myeloproliferative Neoplasms
3910 - Acute Myeloid Leukemia Cells Rely on the Glycolytic Enzyme PGK1 to Support Energy Production and Amino Acid Metabolism
2997 - ERK2 Substrate Binding Domains Play Distinct Roles in Megakaryocytic-Erythroid Lineage Progression and Mediates Clonal Fitness in Myeloproliferative Neoplasms
3910 - Acute Myeloid Leukemia Cells Rely on the Glycolytic Enzyme PGK1 to Support Energy Production and Amino Acid Metabolism
Martinez, G.
Martinez Hernandez, R.
Martinez Iniesta, M.
Martinez, I.
Martinez, J. A.
Martinez Lopez, J.
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
3536 - COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies
4818 - The Augmented Hematologist: Human-AI Feedback Loops to Assist Differential Cell Count during the Analysis of Bone Marrow Aspirates
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
3536 - COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies
4818 - The Augmented Hematologist: Human-AI Feedback Loops to Assist Differential Cell Count during the Analysis of Bone Marrow Aspirates
Martinez Losada, M. C.
Martinez, M. R.
Martínez Montalbán, E.
Martínez Moreno, E.
Martinez Munoz, M. C.
269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
2063 - Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT
2082 - Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
3391 - Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis
2063 - Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT
2082 - Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
3391 - Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis
Martínez Olmos, P.
Martinez Sanchez, P.
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Martínez Sánchez, P.
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
Martinez, S.
Martinez, T. C.
Martinez Tovar, A.
Martínez-Alfonzo, I.
Martinez-Barranco, P.
Martinez-Calle, N.
153 - Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
Martínez-Cibrián, N.
Martínez-Cibrian, N.
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
2063 - Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT
2082 - Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT
3391 - Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis
2063 - Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT
2082 - Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT
3391 - Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis
Martinez-Climent, J. A.
Martinez-Cordero, H.
3199 - Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup
4244 - Treatment Patterns and Survival of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma in Latin America
4244 - Treatment Patterns and Survival of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma in Latin America
Martinez-Cuadron, D.
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4042 - Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4042 - Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Martinez-Cuadron, D.
Martínez-Flores, S.
Martínez-Gallo, M.
Martínez-García, M.
Martinez-Lage, M.
Martinez-Laperche, C.
Martinez-Lopez, J.
99 - Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
Martínez-Lopez, J.
Martínez-López, J.
118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
1526 - Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
4926 - Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
1526 - Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
4926 - Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021
Martinez-Lopez, J.
159 - Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
1882 - Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket
1882 - Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket
Martinez-Lopez, J.
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
Martinez-Maza, O.
Martínez-Roca, A.
Martinez-Sanchez, J.
Martini, N.
Martino, B.
Martino, C. H.
Martino, M.
Martino, R.
164 - Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30+ T-Cell Lymphoma: Clinical and Biological Studies
4631 - Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry
4631 - Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry
Martino, S.
Martino, S.
Martins, A. C.
Martins, C.
Martins, T. J.
Martins-Gonçalves, R.
Martinucci, P.
Martinuzzi, C.
Martire, B.
Martorana, E.
Martos-Rus, C.
Marty, C.
6 - Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)
3723 - Oral SGLT2 Inhibitors in Glycogen Storage Disease Type Ib and G6PC3-Deficiency. Preliminary Results from an Off-Label Study of 21 Patients
3723 - Oral SGLT2 Inhibitors in Glycogen Storage Disease Type Ib and G6PC3-Deficiency. Preliminary Results from an Off-Label Study of 21 Patients
Martycz, M.
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
Martynova, A.
Maruff, P.
Marullo, R.
Marumo, A.
Maruoka, H.
Marupudi, A.
Maruta, M.
Maruyama, D.
1570 - Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma
1614 - Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
1614 - Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
Maruyama, H.
Maruyama, Y.
Marx, A.
Marx, J.
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
3377 - Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease
3377 - Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease
Mary, C.
Maryamchik, E.
Marzac, C.
Marzbani, E. A.
Marzolini, M. A.
Marzollo, A.
Marzuttini, F.
Mas, G.
Mas Martin, G.
Masaki, Y.
Masalu, N.
4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
Masamoto, Y.
Masaquel, A.
2958 - Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
3527 - Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
3527 - Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Masarova, L.
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
619 - Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
1441 - Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
1716 - Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
2729 - A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
3044 - Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
4038 - The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms
4078 - Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
4353 - Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years
4401 - Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome
619 - Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
1441 - Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
1716 - Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
2729 - A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
3044 - Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
4038 - The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms
4078 - Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
4353 - Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years
4401 - Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome
Mascarenhas, J.
60 - Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification
238 - Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
628 - Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
630 - Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib
1683 - Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis
1712 - Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
1713 - MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
1735 - Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119
1763 - Characterization of Myeloid Neoplasms in Inflammatory Bowel Disease
2312 - The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
3004 - A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera
3037 - MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
3039 - Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis (MF): An Analysis from MOST
4316 - PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4357 - Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis
238 - Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
628 - Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
630 - Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib
1683 - Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis
1712 - Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
1713 - MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
1735 - Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119
1763 - Characterization of Myeloid Neoplasms in Inflammatory Bowel Disease
2312 - The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
3004 - A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera
3037 - MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
3039 - Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis (MF): An Analysis from MOST
4316 - PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4357 - Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis
Mascarenhas, L.
Mascetti, S.
Maschan, A.
289 - Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial
872 - Tcrαβ+/CD19+-Depletion in Hematopoietic Stem Cells Transplantation from Matched Unrelated and Haploidentical Donors in Pediatric Acute Lymphoblastic Leukemia Patients in Complete Remission
2010 - Allogeneic Donor-Derived Myeloid Antigen Directed CAR-T Cells – for Relapsed/Refractory Acute Myeloid Leukemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Cases
872 - Tcrαβ+/CD19+-Depletion in Hematopoietic Stem Cells Transplantation from Matched Unrelated and Haploidentical Donors in Pediatric Acute Lymphoblastic Leukemia Patients in Complete Remission
2010 - Allogeneic Donor-Derived Myeloid Antigen Directed CAR-T Cells – for Relapsed/Refractory Acute Myeloid Leukemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Cases
Maschan, M.
872 - Tcrαβ+/CD19+-Depletion in Hematopoietic Stem Cells Transplantation from Matched Unrelated and Haploidentical Donors in Pediatric Acute Lymphoblastic Leukemia Patients in Complete Remission
2010 - Allogeneic Donor-Derived Myeloid Antigen Directed CAR-T Cells – for Relapsed/Refractory Acute Myeloid Leukemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Cases
2010 - Allogeneic Donor-Derived Myeloid Antigen Directed CAR-T Cells – for Relapsed/Refractory Acute Myeloid Leukemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Cases
Maschek, S.
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
4813 - A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI
4813 - A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI
Masciulli, A.
Masetti, R.
564 - UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia
1266 - Prospective and Retrospective Observational Study in Adult and Pediatric Patients with GATA2 Variants (GATA2 Deficiency)
3878 - Mesenchymal Stromal Cell Secretome in Acute Myeloid Leukemia Bone Marrow Niche
1266 - Prospective and Retrospective Observational Study in Adult and Pediatric Patients with GATA2 Variants (GATA2 Deficiency)
3878 - Mesenchymal Stromal Cell Secretome in Acute Myeloid Leukemia Bone Marrow Niche
Mashima, K.
Masias, C.
Mašić, D.
Masih-Khan, E.
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
Masih-Khan, E.
117 - Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
1898 - Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
1898 - Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
Masih-Khan, E.
Maslah, N.
235 - Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
326 - JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms
341 - Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification
1494 - Reduced MDM2 and MDM4 Protein, but Not mRNA, Expression Is Associated with More Severe Disease in Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomoncytic Leukemia (CMML)
1675 - Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction
3932 - Canonical Thrombopoietin Receptor Mutants in Myeloproliferative Neoplasms Rely Differently on the Extracellular Domain of the Receptor but Share Similar Mechanisms of Inactivation: An Open Field for the Development of New Therapies
326 - JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms
341 - Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification
1494 - Reduced MDM2 and MDM4 Protein, but Not mRNA, Expression Is Associated with More Severe Disease in Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomoncytic Leukemia (CMML)
1675 - Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction
3932 - Canonical Thrombopoietin Receptor Mutants in Myeloproliferative Neoplasms Rely Differently on the Extracellular Domain of the Receptor but Share Similar Mechanisms of Inactivation: An Open Field for the Development of New Therapies
Maslawska-Wasowska, K.
Masmanidou, M.
Masmas, T. N.
Mason, C. E.
703 - Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma
1341 - Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease
1341 - Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease
Mason, E. F.
39 - Programmed Death-1 Homolog (PD-1H/VISTA) Blockade Confers a Synergistic Anti-Leukemia Effect with PD-1 Blockade
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site
Mason, J.
Masone, K.
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
4570 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
4570 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Masood, A.
115 - Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
4277 - R-CHOP Versus R-EPOCH in Primary Mediastinal Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
4733 - Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
4277 - R-CHOP Versus R-EPOCH in Primary Mediastinal Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
4733 - Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
Masood, A.
439 - YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
656 - Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
656 - Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Masouleh, B. K.
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
3319 - ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
3319 - ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Masouridi-Levrat, S.
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
4715 - T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients
4715 - T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Massa, A.
Massaad, E.
Massaccesi, E.
Massaia, M.
Massarenti, L.
Massaro, S.
Massat, B.
Massberg, S.
Masselink, L. E.
Massey, J. K.
Massidda, S.
Massie, A.
Masson Frenet, E.
Masson, J. Y.
Massoni, R.
Massoud, R.
Mast, A. E.
Mastaglio, S.
Master, S. R.
1067 - Incidence of VTE in Pregnant Women with Sickle Cell Gene Mutation(s): A Retrospective Database Analysis
2196 - ADAMTS13 Overtesting in Hospitalized Patients with Suspected TTP: A Retrospective Study
4881 - Outcomes in Pregnant HbSS and HbSβ0-Thalassemia Sickle Cell Disease Patients Receiving Scheduled Exchange Transfusions: A Retrospective Study
2196 - ADAMTS13 Overtesting in Hospitalized Patients with Suspected TTP: A Retrospective Study
4881 - Outcomes in Pregnant HbSS and HbSβ0-Thalassemia Sickle Cell Disease Patients Receiving Scheduled Exchange Transfusions: A Retrospective Study
Masternak, A.
Masters, G.
Masterson, T.
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
Mastey, V.
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
Mastrodicasa, E.
Masucci, C.
Masuda, E.
Masuda, S.
Masuda, T.
Masuko, M.
2100 - Breadth of the Human Leukocyte Antigens Class I Immunopeptidome in Allogenic Hematopoietic Stem Cell Transplantation Outcomes for Myeloid Malignancy
3454 - HLA-B Leader Mismatch Positively Correlates with Survival Rate in Haplo and Cord Blood Transplantation for Acute Leukemia in Japanese Patients
3454 - HLA-B Leader Mismatch Positively Correlates with Survival Rate in Haplo and Cord Blood Transplantation for Acute Leukemia in Japanese Patients
Masuya, M.
Mata, D. A.
Mata Vazquez, M. I.
Mata-Rocha, M.
Matar, S.
Matarasso Greenfeld, S.
Matasar, M. J.
442 - Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
610 - Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
1576 - Population Pharmacokinetics and Exposure–Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
2844 - LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients
2865 - Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
2882 - Pooled Safety Analysis from Phase I–III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
610 - Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
1576 - Population Pharmacokinetics and Exposure–Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
2844 - LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients
2865 - Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
2882 - Pooled Safety Analysis from Phase I–III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
Matatall, K. A.
Mate, J. L.
Mateos, M. V.
99 - Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)
118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
567 - Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
1936 - Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
2014 - Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data
2023 - DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
3254 - Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
3278 - Identification of Molecular Mechanisms Governing CAR-T Cell Response in MM Patients Using Single Cell Transcriptomics
4561 - Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study
4648 - CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
567 - Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
1936 - Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
2014 - Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data
2023 - DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)
2028 - Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
3254 - Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
3278 - Identification of Molecular Mechanisms Governing CAR-T Cell Response in MM Patients Using Single Cell Transcriptomics
4561 - Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study
4648 - CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
Mateos Pérez, J. M.
Mateos-Jaimez, J.
Matern, W. M.
Materna, C.
Materozzi, M.
Mateus, A.
Mateus, E. A.
Mathas, S.
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
736 - High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients – a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
736 - High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients – a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)
Mathavan, K.
Mather, E.
Mathew, B. S.
Mathew, S. K.
Mathews, R.
Mathews, V.
1397 - Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
1407 - Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
2069 - A Model-Informed Precision Busulfan Dosing in Pediatric Patients Undergoing Hematopoietic Cell Transplantation- Real-World Data
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
3828 - New CMC Algorithm for Evaluation of Lupus Anticoagulant
4020 - Intracranial Bleeding in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide-Based Regimens: Impact on Relapse and Survival
4317 - Rxra Overexpression Improves the Sensitivity to Imatinib In-Vitro/in-Vivo By Disrupting the Oxidative Capacity of Chronic Myeloid Leukemia Cells
4698 - Population Pharmacokinetics of Mycophenolic Acid in Haploidentical Transplant Recipients Receiving Post-Transplant Cyclophosphamide Based GvHD Prophylaxis
1407 - Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
2069 - A Model-Informed Precision Busulfan Dosing in Pediatric Patients Undergoing Hematopoietic Cell Transplantation- Real-World Data
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
3828 - New CMC Algorithm for Evaluation of Lupus Anticoagulant
4020 - Intracranial Bleeding in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide-Based Regimens: Impact on Relapse and Survival
4317 - Rxra Overexpression Improves the Sensitivity to Imatinib In-Vitro/in-Vivo By Disrupting the Oxidative Capacity of Chronic Myeloid Leukemia Cells
4698 - Population Pharmacokinetics of Mycophenolic Acid in Haploidentical Transplant Recipients Receiving Post-Transplant Cyclophosphamide Based GvHD Prophylaxis
Mathewson, N. D.
Mathier, B.
Mathieu, F.
Mathilde, H. B.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
Mathioudaki, A.
309 - Single-Cell Multi-Omic and Spatial Analysis of Nodal B Cell Non-Hodgkin Lymphomas Reveals Plasticity in B Cell Maturation As a Driver of Intratumor Heterogeneity
2554 - Unraveling and Visualizing the Interactions of Acute Myeloid Leukemia with the Bone Marrow Microenvironment in Vitro and In Vivo
2554 - Unraveling and Visualizing the Interactions of Acute Myeloid Leukemia with the Bone Marrow Microenvironment in Vitro and In Vivo
Mathis, S.
Mathur, S.
Mathyer, M. E.
Matin, A.
Matino, D.
Matissek, S. J.
Matlawski, T.
Mato, A. R.
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
348 - Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
1808 - Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia
1809 - Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years
3122 - Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
3132 - Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
3133 - Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
3597 - A Timelapse of Patient and Provider Care Perceptions and Educational Needs for CLL over Three Years of Tailored Educational Interventions
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4256 - Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
- Adult Clinical Malignant Hematology
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
348 - Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
1808 - Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia
1809 - Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years
3122 - Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
3132 - Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
3133 - Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
3597 - A Timelapse of Patient and Provider Care Perceptions and Educational Needs for CLL over Three Years of Tailored Educational Interventions
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4256 - Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
- Adult Clinical Malignant Hematology
Matos, E.
Matous, J. V.
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
1933 - A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
4491 - Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
1933 - A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
4491 - Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
Matrejek, A.
1310 - PIM Kinases Regulate Super-Enhancer-Dependent Gene Expression in Diffuse Large B-Cell Lymphoma
1822 - Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703
1822 - Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703
Matsubara, C.
Matsubayashi, J.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
Matsuda, K.
Matsuda, K.
Matsuda, S.
Matsue, K.
756 - Anti-Sars-Cov-2 Antibody and T-Cell Responses Using Deep T-Cell Receptor Immunosequencing after Vaccination Among Healthy Individuals and Patients with Multiple Myeloma or Lymphoma
2977 - Prospective Study of the Usefulness of Liquid Biopsy in Patients with Unknown Fever Suspected of Malignant Lymphoma
3941 - Single-Cell Transcriptome Reveals Comprehensive Immune Profiles of T Follicular Helper Cell Lymphoma
4179 - Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
2977 - Prospective Study of the Usefulness of Liquid Biopsy in Patients with Unknown Fever Suspected of Malignant Lymphoma
3941 - Single-Cell Transcriptome Reveals Comprehensive Immune Profiles of T Follicular Helper Cell Lymphoma
4179 - Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
Matsui, W.
Matsukawa, T.
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
Matsuki, E.
Matsumoto, K.
Matsumoto, M.
137 - Neonatal Exchange Transfusion: When Should We Think about Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)?
1172 - Differential Diagnosis Distinguishing Immune TTP from Septic DIC Using Plasma Levels of Haptoglobin and Factor XIII Activity
1183 - ADAMTS13 Conformation and Immunoprofiles in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura
1172 - Differential Diagnosis Distinguishing Immune TTP from Septic DIC Using Plasma Levels of Haptoglobin and Factor XIII Activity
1183 - ADAMTS13 Conformation and Immunoprofiles in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura
Matsumura, A.
Matsumura, A.
Matsumura, I.
54 - Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study
2687 - Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
3882 - Efficacy and Safety of Long-Term Romiplostim Use for Refractory Aplastic Anemia
2687 - Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
3882 - Efficacy and Safety of Long-Term Romiplostim Use for Refractory Aplastic Anemia
Matsuno, Y.
Matsuoka, A.
Matsuoka, K. I.
876 - The Novel Scoring System to Personalize the Conditioning Intensity in Elderly Patients
990 - Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
1427 - Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
4579 - Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age
990 - Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
1427 - Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
4579 - Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age
Matsuoka, M.
Matsushita, T.
1154 - The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results
2475 - Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
3559 - Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study
2475 - Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
3559 - Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study
Matsuzaka, T.
Mattar, B.
4673 - Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4910 - Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study
4910 - Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study
Mattavelli, G.
Mattè, A.
Mattei, R.
Matteo Bühler, M.
Matthews, A.
Matthews, J.
Mattie, M.
165 - Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site
261 - Durable Response to CD19 CAR T Cell Therapy Is Associated with Cytotoxicity and Clonotypic Expansion of the Native T Cell Repertoire
440 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
1981 - Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial
2039 - Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
4610 - Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19
261 - Durable Response to CD19 CAR T Cell Therapy Is Associated with Cytotoxicity and Clonotypic Expansion of the Native T Cell Repertoire
440 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
1981 - Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial
2039 - Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
4610 - Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19
Mattis, S.
Mattison, R. J.
714 - Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
2717 - Impact of Early Hospitalization, Medical Comorbidities and Allogeneic Stem Cell Transplantation on Survival in Acute Myeloid Leukemia Patients Treated with Venetoclax Based Therapy – a Single Institution Experience from an Academic Center
3635 - Neighborhood Disadvantage, Insurance Status, and Molecular Profiling of Patients with Acute Myeloid Leukemia
4863 - A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
2717 - Impact of Early Hospitalization, Medical Comorbidities and Allogeneic Stem Cell Transplantation on Survival in Acute Myeloid Leukemia Patients Treated with Venetoclax Based Therapy – a Single Institution Experience from an Academic Center
3635 - Neighborhood Disadvantage, Insurance Status, and Molecular Profiling of Patients with Acute Myeloid Leukemia
4863 - A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
Mattlener, J.
Mattos, É. R.
Mattour, A. H.
Mattson, B.
Mattson, J.
Mattsson, J.
2127 - Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
3365 - Substantial Alteration of Allogeneic Stem Cell Grafts Imposed By COVID-19 Pandemic Related Recommendations
3395 - ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies
3411 - Real-World Experience with Ruxolitinib Therapy for Steroid Refractory Acute Graft Versus Host Disease
4737 - Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse
3365 - Substantial Alteration of Allogeneic Stem Cell Grafts Imposed By COVID-19 Pandemic Related Recommendations
3395 - ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies
3411 - Real-World Experience with Ruxolitinib Therapy for Steroid Refractory Acute Graft Versus Host Disease
4737 - Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse
Mattsson, J.
Mattsson, M.
Matusiak, K.
Matytsina, I.
Maude, S. L.
983 - CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
Maughn, K.
Mauguen, A.
2445 - A Single Institutional Experience Using Romiplostim to Manage Treatment Related Thrombocytopenia in Pediatric Solid Tumor Patients
3455 - Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL
3455 - Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL
Maupin, B.
Maura, F.
100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
101 - Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
637 - Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma
638 - Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma
643 - Tracking the Earliest Genomic Events in Multiple Myeloma Life-History
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
1852 - Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
3170 - The Mutagenic Impact of Radiotherapy in Multiple Myeloma
101 - Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
637 - Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma
638 - Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma
643 - Tracking the Earliest Genomic Events in Multiple Myeloma Life-History
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
1852 - Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
3170 - The Mutagenic Impact of Radiotherapy in Multiple Myeloma
Maurer, D.
Maurer, K.
Maurer, M. S.
Maurer, M. J.
Maurer, M. J.
313 - Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
793 - Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
798 - Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
850 - Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
2966 - Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
4156 - Molecular Landscape of Primary Refractory DLBCL
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
793 - Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
798 - Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
850 - Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
2966 - Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
4156 - Molecular Landscape of Primary Refractory DLBCL
Maurer, V.
Mauri, M.
1358 - Effects of CD24 "Don’t Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma
2674 - Activina : A Key Factor Mediating Chemoresistance in B-Cell Type Acute Lymphoblastic Leukemia
3977 - The RNA Binding Protein Musashi-2 (MSI2) Sustains the Growth and the Leukemogenic Potential of MLL-Rearranged Acute Lymphoblastic Leukemia, and It Is Involved in Glucocorticoid Resistance
2674 - Activina : A Key Factor Mediating Chemoresistance in B-Cell Type Acute Lymphoblastic Leukemia
3977 - The RNA Binding Protein Musashi-2 (MSI2) Sustains the Growth and the Leukemogenic Potential of MLL-Rearranged Acute Lymphoblastic Leukemia, and It Is Involved in Glucocorticoid Resistance
Maurice-Stam, H.
Mauriello, A.
Maurillo, L.
1382 - The Added Value of Multi‐State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis
4041 - Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia
4356 - Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events
4041 - Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia
4356 - Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events
Mauro, F. R.
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1817 - Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence
3131 - Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL
1817 - Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence
3131 - Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL
Mauro, M.
84 - Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
3011 - Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study
3018 - First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies
3020 - ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)
3044 - Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
4327 - A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
3011 - Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study
3018 - First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies
3020 - ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)
3044 - Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
4327 - A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
Maury, S.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
Maus, M. V.
207 - Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas
262 - Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel
3047 - Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
4616 - Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
262 - Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel
3047 - Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
4616 - Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Mauvieux, L.
Maverakis, E.
Mavilio, D.
Mavis, C.
Mavrianou-Koutsoukou, N.
Mavrianou-Koutsoukou, N.
Mavroudi, I.
Mavroukakis, S.
Mawad, R.
1634 - Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
4555 - Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
4555 - Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
Maximova, N.
Maxson, J. E.
Maxwell, D.
Maxwell, K. N.
May, J.
May, J. E.
502 - Rethinking the Gold Standard: Real-World Performance of the Serotonin Release Assay (SRA) and PF4-Dependent P-Selectin Expression Assay (PEA) in the Diagnosis of Heparin-Induced Thrombocytopenia (HIT)
667 - The Performance of Electronic Consultation in Non-Malignant Hematology in a Fee-for-Service Care Delivery Model
- ASH Guideline Implementation Project
667 - The Performance of Electronic Consultation in Non-Malignant Hematology in a Fee-for-Service Care Delivery Model
- ASH Guideline Implementation Project
May, S. B.
Mayberry, K.
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
3465 - Increased Potency and Uniformity of Fetal Hemoglobin Induction from Base Editing Compared to Cas9 Nuclease
4782 - Base Editing for Therapeutic Induction of Fetal Hemoglobin in β-Thalassemia
3465 - Increased Potency and Uniformity of Fetal Hemoglobin Induction from Base Editing Compared to Cas9 Nuclease
4782 - Base Editing for Therapeutic Induction of Fetal Hemoglobin in β-Thalassemia
Mayer, J. L.
Mayer, J.
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
230 - Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
336 - Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
3015 - The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
3019 - Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure
4345 - Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
230 - Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
336 - Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
3015 - The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
3019 - Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure
4345 - Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
Mayer, J.
80 - Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA
1693 - Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
1693 - Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Mayer, K.
Mayer, R. J.
Mayer, S. A.
Mayerhoefer, M. E.
Mayerhofer, C.
Mayeur-Rousse, C.
Mayhew, L. M.
Mayman, N.
Maynard, R. S.
351 - Malignant Plasma Cell Derived Mitochondrial Damps Activate Macrophages Via Sting Signalling to Promote Myeloma Development
2548 - LC3-Associated Phagocytosis Is Impaired in Bone Marrow Macrophages during Ageing Leading to Defective Processing of Apoptotic Cells and Suppression of Sting Activation
3852 - Mitochondrial Membrane Potential Defines the HSC Population with Serial Repopulating Potential in Young but Not Aged Animals
4096 - Sting Agonists Activate Bone Marrow Macrophages and Synergise with Anti-CD47 Blockade Improving Survival in Animal Models of Acute Myeloid Leukemia
2548 - LC3-Associated Phagocytosis Is Impaired in Bone Marrow Macrophages during Ageing Leading to Defective Processing of Apoptotic Cells and Suppression of Sting Activation
3852 - Mitochondrial Membrane Potential Defines the HSC Population with Serial Repopulating Potential in Young but Not Aged Animals
4096 - Sting Agonists Activate Bone Marrow Macrophages and Synergise with Anti-CD47 Blockade Improving Survival in Animal Models of Acute Myeloid Leukemia
Maynes, M.
Mayo, L.
Mayo, M.
Mayo, S. J.
Mayor Bastida, C.
Mayor, E.
213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
Mayor-Bastida, C.
Mayotte, N.
Mayuranathan, T.
Mazahreh, F.
Mazahreh, L.
Maze, D.
1371 - Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers
1372 - Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?
1375 - Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up
1380 - Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience
2691 - Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol
4037 - Clinical Outcomes in De Novo Versus Secondary NPM1-Mutated AML
4109 - The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy
4324 - Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
4370 - Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor
1372 - Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?
1375 - Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up
1380 - Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience
2691 - Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol
4037 - Clinical Outcomes in De Novo Versus Secondary NPM1-Mutated AML
4109 - The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy
4324 - Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
4370 - Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor
Maze, M.
Mazepa, M.
Mazetto, B. M.
Mazhab-Jafari, M.
Maziarz, R. T.
151 - Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma
657 - Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4649 - JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function
4865 - Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
657 - Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4649 - JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function
4865 - Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
Mazimba, C.
Mazloom, A.
Mazumder, S.
Mazurier, C.
Mazza, P.
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
Mazza, R.
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
Mazzacurati, L.
Mazzi, F.
Mazziotta, F.
Mazzocchetti, G.
Mazzola, M.
Mazzolai, L.
Mazzoleni, S.
Mazzon, F.
Mazzone, A.
Mazzoni, C.
3625 - Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study
3761 - Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study
3761 - Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study
Mazzoni, S.
1868 - Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4826 - Managing Kidney Disease in Patients with Sickle Cell Disease: A Quality Initiative at the Cleveland Clinic
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4826 - Managing Kidney Disease in Patients with Sickle Cell Disease: A Quality Initiative at the Cleveland Clinic
MB, D.
3330 - Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)
4646 - Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)
4646 - Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)
Mbofung, R. M.
481 - Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection
1986 - Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy
3288 - iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
1986 - Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy
3288 - iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
Mbong, N.
Mbulaiteye, S. M.
393 - Pklr Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
Mbunya, S. M.
Mbuyi, T.
McAfee, S.
McAlister, A.
McAllen, S.
McArthur, M. J.
McAuley, G.
McAvera, R. M.
McAvoy, D. P.
McBane, R. D.
McBride, A.
389 - Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns
889 - Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
2312 - The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
4023 - Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
4412 - Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes
4941 - Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
889 - Cost-Effectiveness Analyses of First Line Ibrutinib Versus Acalabrutinib Versus Zanubrutinib Followed By Second Line Venetoclax Plus Rituximab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
2312 - The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
4023 - Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
4412 - Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes
4941 - Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
McBride, A.
McCabe, C.
McCachren, S.
McCafferty, J.
McCall, C. M.
1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
McCann, C.
McCarten, K. M.
McCarter, A.
McCarter, J.
McCarthy, H.
McCarthy, P. L.
270 - Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
3997 - β2-AR Signaling Enhances MDSC Survival through Metabolic Reprograming and Impairs Therapeutic Efficacy in Hematologic Malignancies
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders
4635 - ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma
4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
3997 - β2-AR Signaling Enhances MDSC Survival through Metabolic Reprograming and Impairs Therapeutic Efficacy in Hematologic Malignancies
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders
4635 - ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma
4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT
McCarty, J. M.
875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
McCarty, K. L.
McCarty, O. J.
McCarville, M. B.
McClain, K. L.
McClatchy, J.
McClellan, J. S.
265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
3408 - Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
3408 - Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T
McClory, S. E.
983 - CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells
2416 - Trib1 Inhibition Promotes the Klr Effector State and Augments Checkpoint Blockade to Enhance T Cell Function during T Cell Exhaustion
2416 - Trib1 Inhibition Promotes the Klr Effector State and Augments Checkpoint Blockade to Enhance T Cell Function during T Cell Exhaustion
McCloskey, J.
933 - Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax
2789 - DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy
2789 - DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy
McCloskey, J.
240 - Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
1436 - V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
1436 - V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
McCloskey, J. K.
McClune, B.
McClure, R.
McCole, R.
McConnell, A.
McConnell, K.
McConnell, M.
McConville, C.
McCook, A. A.
McCormack, M. P.
McCormick, M.
McCoy, J. W.
McCrae, K. R.
McCrory, A.
McCue, D.
McCullough, K.
537 - Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
1233 - Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
1233 - Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
McCune, P.
McCurdy, A.
117 - Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
173 - Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada
991 - Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
3248 - Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
173 - Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada
991 - Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
3248 - Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
McCurdy, S. R.
McCurdy, S. R.
426 - Real World Effectiveness of “7 + 3” Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia
4862 - Fried’s Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
4862 - Fried’s Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
McDaniel, S. A.
McDavid, A.
McDermott, D. H.
McDonagh, C. F.
1955 - Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease
McDonald, A.
McDonald, T.
McDonald, V.
3 - Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
1012 - Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience
1128 - Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)
1132 - Comparative Effectiveness of Fostamatinib Vs. Rituximab in Refractory Chronic Immune Thrombocytopenia: A Network Meta-Analysis
1012 - Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience
1128 - Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)
1132 - Comparative Effectiveness of Fostamatinib Vs. Rituximab in Refractory Chronic Immune Thrombocytopenia: A Network Meta-Analysis
McDonald, Z.
McDonald-Hyman, C.
McDonnell, T. J.
McDonough, K.
McDonough, M. M.
490 - A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
1806 - Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients
4433 - Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
1806 - Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients
4433 - Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
McElhinney, K.
McEvoy, D.
McFadden, M.
McFadyen, J. D.
McFaline Figueroa, J.
McGann, P. T.
2192 - Assessment of Emergency Department Care for Patients with Acute Pain Crisis after the Formation of a Multidisciplinary Team
2377 - Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial
2380 - Optimizing Dose and Limiting Laboratory Monitoring of Hydroxyurea in Africa: Design of the Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSH-UP) Trial
3649 - Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT)
2377 - Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial
2380 - Optimizing Dose and Limiting Laboratory Monitoring of Hydroxyurea in Africa: Design of the Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSH-UP) Trial
3649 - Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT)
McGee, B.
1010 - Next Generation Sequencing for the Diagnosis of Hereditary Hemolytic Anemias Including Pyruvate Kinase Deficiency: Report from a No-Cost Diagnostic Program
2328 - Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
2329 - Comorbidities and Complications in Pediatric Patients with Pyruvate Kinase Deficiency Enrolled in the Peak Registry
2332 - Age of Onset of Complications in Patients with Pyruvate Kinase Deficiency: Analysis from the Peak Registry
2328 - Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
2329 - Comorbidities and Complications in Pediatric Patients with Pyruvate Kinase Deficiency Enrolled in the Peak Registry
2332 - Age of Onset of Complications in Patients with Pyruvate Kinase Deficiency: Analysis from the Peak Registry
McGeehan, G. M.
McGeehan, G. M.
McGhie, A.
McGill, Á. E.
McGlothlin, J.
McGough, S. F.
McGovern, A. S.
McGrath, K. E.
McGraw, K. L.
McGree, J.
McGregor, A.
Mcgregor, C.
McGregor, K.
McGuckin, C.
359 - A Novel Human OX40L-CAR-Treg Specifically Targets Activated Antigen-Presenting Cells and Effectively Controls T Cell Alloreactivity and Xeno-GvHD
482 - CAR-T Cell Infusion Results in Activation of CD160+/NKG2D+/CCL5+ Non-CAR CD8+ Cytotoxic ‘Bystander’ T Cells in Both Non-Human Primates (NHP) and Patients Receiving B-Cell-Directed CAR-Ts
482 - CAR-T Cell Infusion Results in Activation of CD160+/NKG2D+/CCL5+ Non-CAR CD8+ Cytotoxic ‘Bystander’ T Cells in Both Non-Human Primates (NHP) and Patients Receiving B-Cell-Directed CAR-Ts
McGuinn, C. E.
McGuinness, M.
McGuirk, J. P.
151 - Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma
252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
657 - Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
659 - Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
2000 - Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC‑Derived TCR‑Less CD19 CAR T‑Cell Therapy for Patients with Relapsed/Refractory B‑Cell Malignancies
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
3323 - Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial
3335 - A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4686 - PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
4703 - Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
657 - Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
659 - Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
2000 - Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC‑Derived TCR‑Less CD19 CAR T‑Cell Therapy for Patients with Relapsed/Refractory B‑Cell Malignancies
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
3323 - Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial
3335 - A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
4686 - PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
4703 - Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients
4750 - Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
McIntosh, J.
1525 - Targeting the HSP90-MYC-CDK9 Axis to Overcome Dual Resistance to BTK Inhibition and CAR-T Therapy in Mantle Cell Lymphoma
2850 - HSP27 Promotes Mantle Cell Lymphoma Growth and Mediates Resistance to Venetoclax
2870 - Modulating Immunometabolism to Reinvigorate T-Cell Effector Function and Antitumor Immunity in the Mantle Cell Lymphoma Microenvironment
4155 - Establishment of a Patient-Derived Organoid Culture Platform for Mantle Cell Lymphoma Drug Sensitivity and CAR T Cell Anti-Tumor Activity Assay
2850 - HSP27 Promotes Mantle Cell Lymphoma Growth and Mediates Resistance to Venetoclax
2870 - Modulating Immunometabolism to Reinvigorate T-Cell Effector Function and Antitumor Immunity in the Mantle Cell Lymphoma Microenvironment
4155 - Establishment of a Patient-Derived Organoid Culture Platform for Mantle Cell Lymphoma Drug Sensitivity and CAR T Cell Anti-Tumor Activity Assay
Mcintyre, S.
McIver, A.
McKay, P.
153 - Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis
234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
950 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
954 - Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
2959 - Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)
4298 - R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation
234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
950 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
954 - Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
2959 - Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)
4298 - R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation
McKay, V.
McKenna, D. R.
2042 - Utility of Targeted Neurocognitive Testing in Detecting Early Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CAR T-Cell Therapy
3622 - Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display
3622 - Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display
McKeown, M.
McKiernan, P.
McKinley, K.
Mckinney, C.
McKinney, M.
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
McKinney, S.
McKinney-Freeman, S.
McKinnon, K.
McLaughlin, C.
McLaughlin, E.
777 - Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
2891 - Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
2963 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
2891 - Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
2963 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
McLemore, A. F.
McLemore, M. L.
McLeod, J.
McLeod, J. L.
920 - Discovery of a New Human Hematopoietic Stem Cell Involved with Aging That Retains Memory of Immune Activation
3365 - Substantial Alteration of Allogeneic Stem Cell Grafts Imposed By COVID-19 Pandemic Related Recommendations
3905 - Identification of Global miRNA Targetomes within Human Hematopoietic Progenitors and Acute Myeloid Leukemia Uncovers Unique Molecular Networks Centered on Mitochondria Function in Leukemic Stem Cells
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
3365 - Substantial Alteration of Allogeneic Stem Cell Grafts Imposed By COVID-19 Pandemic Related Recommendations
3905 - Identification of Global miRNA Targetomes within Human Hematopoietic Progenitors and Acute Myeloid Leukemia Uncovers Unique Molecular Networks Centered on Mitochondria Function in Leukemic Stem Cells
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
McLornan, D. P.
McLornan, D. P.
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
371 - Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
627 - Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2114 - Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
2130 - Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3028 - Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum
3376 - Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib
4680 - Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
4759 - Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis
371 - Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
627 - Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2114 - Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
2130 - Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3028 - Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum
3376 - Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib
4680 - Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
4759 - Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis
McMahon, C. M.
1421 - Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study
1444 - Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
2751 - Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza
2753 - Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia
4129 - Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia
1444 - Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
2751 - Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza
2753 - Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia
4129 - Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia
McMahon, C.
McMahon, D.
McMahon, J.
McMahon, J.
McMahon, K. M.
McMahon, T. J.
McMillan, A. K.
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
735 - Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
951 - A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update
3347 - Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
4265 - Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
735 - Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
951 - A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update
3347 - Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom
4260 - Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
4265 - Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
McMillan, M.
McMorran, B. J.
McMullan, H.
McMullin, M. F.
237 - The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
829 - High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML
1115 - Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
3006 - UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
829 - High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML
1115 - Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
3006 - UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
McMurray, H. R.
McMurry, H. S.
McNally, D.
McNally, G. A.
McNamara, C.
McNaughton, A. J.
McNaull, M. A.
McNeely, K.
McNeely, S. R.
McNeer, E.
McNeil, J. J.
930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression
McNeil, R.
McNeill, A. M.
McNerney, K.
McNerney, M. E.
McNinch, C. M.
McPhee, G.
McPherson, A.
McQuilten, Z.
133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19
930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression
4496 - Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from Mrdr Australia and New Zealand
930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression
4496 - Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from Mrdr Australia and New Zealand
McSweeney, P. A.
McWeeney, S. K.
427 - Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy
1324 - The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist
3953 - Characterize Biomarkers and Mechanisms of Resistance for MDM2 Inhibitors in AML
- AI Challenges in Regulatory Approvals and Explainability
1324 - The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist
3953 - Characterize Biomarkers and Mechanisms of Resistance for MDM2 Inhibitors in AML
- AI Challenges in Regulatory Approvals and Explainability
Meacham, L. R.
579 - Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study
582 - Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study
- Decision Making for Reproductive Health in Sickle Cell Disease
582 - Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study
- Decision Making for Reproductive Health in Sickle Cell Disease
Mead, A. J.
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
453 - Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
4363 - Quantitative MRI Detects Multi-Organ Impairment in Patients with Chronic Myeloid Neoplasms
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment
4382 - Single-Cell Transcriptome Analysis Reveals Pathways That Drive Dyserythropoiesis in Myelodysplastic Syndromes, Which Are Targeted By Luspatercept
453 - Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
4363 - Quantitative MRI Detects Multi-Organ Impairment in Patients with Chronic Myeloid Neoplasms
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment
4382 - Single-Cell Transcriptome Analysis Reveals Pathways That Drive Dyserythropoiesis in Myelodysplastic Syndromes, Which Are Targeted By Luspatercept
Mead, M.
4225 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis
4743 - A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E‑CELERATE) (NCT05181540) - Trials in Progress
4743 - A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E‑CELERATE) (NCT05181540) - Trials in Progress
Mead-Harvey, C.
Meade, B.
Meader, E.
Meadors, P. L.
Meadows, G. T.
Meads, M. B.
Meads, M. B.
Meagher, M. M.
Mear, J. B.
Mearns, E. S.
Mearns, E. S.
2317 - Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Receiving ≥3 Lines of Therapy: A Real-World Evaluation in the United States
3085 - Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study
3085 - Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study
Mecklenbrauck, R.
Mecucci, C.
272 - Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML
879 - HLA-Matched Treg/Tcon Allogeneic Hematopoietic Cell Transplantation Is Safe and Ensures Remarkable Chronic GvHD/Leukemia Free Survival in High-Risk Leukemia Patients
1355 - Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia
879 - HLA-Matched Treg/Tcon Allogeneic Hematopoietic Cell Transplantation Is Safe and Ensures Remarkable Chronic GvHD/Leukemia Free Survival in High-Risk Leukemia Patients
1355 - Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia
Medalla, G.
Medawar, G.
Medcalf, R.
Medeiros, B. C.
Medeiros, J.
563 - Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype
960 - Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
1615 - Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
2805 - The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
3492 - Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence
3496 - Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype
960 - Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
1615 - Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
2805 - The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
3492 - Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence
3496 - Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype
Medeiros, J. J.
3019 - Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis
Medeiros, N.
Medeiros, T.
Medhekar, R.
Mediavilla, C.
Mediavilla-Varela, M.
Medik, Y. B.
Medina, A.
Medina, A.
Medina, D.
Medina Inojosa, B. J.
Medina Inojosa, J. R.
Medina, S. D.
1077 - Cognitive Assessment in Brazilian Adults with Sickle Cell Disease (SCD): The Burdens of Sociocultural Background and Correlations with Neuroimaging Findings
4338 - Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response
4338 - Five-Year Follow-up of the Phase I/II Discontinuation Trial of Imatinib after Pioglitazone (EDI-PIO) in Chronic Myeloid Leukemia Patients in Deep Molecular Response
Medina-Echeverz, J.
Medina-González, L.
Medina-Martinez, J. S.
Medina-Martínez, J. S.
Medina-Sanson, A.
Medler, J.
Meduri, E.
Medury, R. K.
Medvedova, E.
1930 - Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
3237 - Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
3237 - Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
Medvedova, E.
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
4527 - Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation
4527 - Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation
Mee, J.
214 - High Dose Methotrexate Does Not Reduce the Risk of CNS Relapse in Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma. Results of the Randomised Phase III Study UKALL 2011
715 - The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
715 - The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Meehan, C.
Meehan, K. R.
880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial
2042 - Utility of Targeted Neurocognitive Testing in Detecting Early Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CAR T-Cell Therapy
3622 - Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display
2042 - Utility of Targeted Neurocognitive Testing in Detecting Early Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CAR T-Cell Therapy
3622 - Patient Reported Outcomes for Patients Receiving a Hematopoietic Stem Cell Transplant: A Longitudinal Assessment with a Dashboard Display
Meeks, S. L.
1140 - Marginal Zone B Cells Facilitate CD4 T Cell Proliferation in Response to Factor VIII in Mice with Hemophilia Α
2440 - Quantitative Platelet Adhesion and Platelet Geometry-Sensing Assays for Evaluating Mild Bleeding Disorders
3805 - Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors
2440 - Quantitative Platelet Adhesion and Platelet Geometry-Sensing Assays for Evaluating Mild Bleeding Disorders
3805 - Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors
Meera Sahib, N. R. B.
Meerding, J. M.
Meermeier, E.
3136 - Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined T Cell Engager and Cytotoxic Therapy in a Multiple Myeloma Preclinical Model
3149 - Key Subsets of Immune Cells in Bone Marrow Myeloid Compartment Indicate Degree of Tumor Infiltration and Avenues for Successful Immunotherapy in Multiple Myeloma
3149 - Key Subsets of Immune Cells in Bone Marrow Myeloid Compartment Indicate Degree of Tumor Infiltration and Avenues for Successful Immunotherapy in Multiple Myeloma
Meers, O.
Meerson, M.
Meeuwsen, M. H.
Megala Costa, L. J.
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
364 - Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
473 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
1930 - Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
2288 - Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy
2299 - Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant
2920 - Survival of Patients with Extranodal NK-Cell Lymphoma in the United States
3166 - Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
3237 - Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
3238 - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
3593 - Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway
4508 - Optimal Sequencing Determination in Relapsed Multiple Myeloma
4527 - Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation
4528 - Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)
4530 - Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
- Discuss historical percentages of URM enrollment in clinical trials and theories for this data
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
364 - Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
473 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN
566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
1930 - Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
2288 - Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy
2299 - Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant
2920 - Survival of Patients with Extranodal NK-Cell Lymphoma in the United States
3166 - Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
3237 - Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
3238 - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
3593 - Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway
4508 - Optimal Sequencing Determination in Relapsed Multiple Myeloma
4527 - Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation
4528 - Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)
4530 - Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
- Discuss historical percentages of URM enrollment in clinical trials and theories for this data
Meggendorfer, M.
228 - AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?
464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1373 - Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
1746 - ANKRD26 Coding Variants in Myeloid Neoplasia
1769 - Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?
- The Application of Machine Learning in Diagnostic Hematology
464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
790 - Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1373 - Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
1746 - ANKRD26 Coding Variants in Myeloid Neoplasia
1769 - Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
3887 - Trisomy-6: The Ying and Yang of Chromosome 6 Aberrations
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?
- The Application of Machine Learning in Diagnostic Hematology
Mehic, D.
Mehta, A.
2169 - Utilizing TCR-Seq to Detect Tabelecleucel, an Allogeneic Epstein–Barr Virus (EBV)-Specific T-Cell Immunotherapy, Post-Infusion
4658 - New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
4658 - New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Mehta, A.
579 - Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study
582 - Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study
582 - Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study
Mehta, A.
3308 - A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK Cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape
4605 - Multi-Antigen Targeting By Novel Combination of CAR-T Cells and hnCD16 Transgene, Yields in Complete Tumor Clearance Via Antibody Dependent Cellular Cytotoxicity
4605 - Multi-Antigen Targeting By Novel Combination of CAR-T Cells and hnCD16 Transgene, Yields in Complete Tumor Clearance Via Antibody Dependent Cellular Cytotoxicity
Mehta, A. R.
Mehta, A.
1618 - Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
1641 - Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens
2000 - Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC‑Derived TCR‑Less CD19 CAR T‑Cell Therapy for Patients with Relapsed/Refractory B‑Cell Malignancies
4214 - Characteristics of Patients with Observation As Initial Treatment Strategy in Mantle Cell Lymphoma
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
1641 - Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens
2000 - Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC‑Derived TCR‑Less CD19 CAR T‑Cell Therapy for Patients with Relapsed/Refractory B‑Cell Malignancies
4214 - Characteristics of Patients with Observation As Initial Treatment Strategy in Mantle Cell Lymphoma
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers
Mehta, A.
Mehta, J.
Mehta, P.
1397 - Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
Mehta, P.
218 - FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
220 - A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
220 - A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
Mehta, R. P.
Mehta, R. S.
265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3333 - A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3422 - Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
4725 - Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
4733 - Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4764 - Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3333 - A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3422 - Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
4725 - Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
4733 - Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4764 - Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
Mehta-Shah, N.
310 - Clonal Evolution of Cutaneous T Cell Lymphoma Revealed at Single Cell Resolution
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
1539 - Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
1631 - Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
4225 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
1539 - Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
1631 - Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
4225 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis
Mehtap, Ö.
Mei, C.
1748 - The Transcriptional Factor ONECUT3 Is a Driver and Therapeutic Target for Complex Karyotype MDS
3066 - The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
3921 - RIPK3 Deficiency Caused By DNA Hypermethylation Blocks R-2-Hydroxyglutarate Induced Necroptosis in AML with IDH Mutation
4389 - EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
4393 - Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Multicenter, Open-Label, Prospective Trial
3066 - The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
3921 - RIPK3 Deficiency Caused By DNA Hypermethylation Blocks R-2-Hydroxyglutarate Induced Necroptosis in AML with IDH Mutation
4389 - EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
4393 - Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Multicenter, Open-Label, Prospective Trial
Mei, H.
257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies
1133 - Different Biomarkers and a Novel Scoring Model for the Prediction of ITP Patients Treated with Corticosteroid Versus TPO-Ras
1994 - Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
4626 - BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System
4636 - Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL
1133 - Different Biomarkers and a Novel Scoring Model for the Prediction of ITP Patients Treated with Corticosteroid Versus TPO-Ras
1994 - Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
4626 - BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System
4636 - Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL
Mei, H.
660 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
Mei, M.
318 - Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
442 - Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
2956 - Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4239 - Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
442 - Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
984 - Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
2956 - Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
4239 - Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Mei, Y.
Meid, K.
231 - Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Meideros, J.
Meier, C.
Meier, E. R.
1058 - Trials in Progress: Two Randomized, Double-Blind, Multicenter, Placebo-Controlled Trials Investigating the Efficacy of Voxelotor on Cerebral Blood Flow and Neurocognitive Function in Patients with Sickle Cell Disease
2377 - Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial
2377 - Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial
Meier, J. A.
Meignin, V.
235 - Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
1554 - Characteristics of Circulating KSHV-Infected Cells during Active KSHV+ Multicentric Castleman Disease
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
1554 - Characteristics of Circulating KSHV-Infected Cells during Active KSHV+ Multicentric Castleman Disease
Meijer, E.
Meijer, K.
591 - Colorectal Cancer Screening in Patients with Inherited Bleeding Disorders: High Cancer Detection Rate in Hemophilia Patients
2475 - Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
2475 - Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study
Meijer, K.
Meijerink, J. P.
Meirson, T.
Meis, R. J.
2408 - Extended Detection in Peripheral Blood Following Infusion of Chronic Granulomatous Disease Patient Autologous Granulocytes Corrected By mRNA Transfection in Patients with Chronic Granulomatous Disease
3456 - Highly Efficient & Specific Repair of MAGT1 Mutation in Xmen Patient T Cells and Hematopoietic Stem Cells
3456 - Highly Efficient & Specific Repair of MAGT1 Mutation in Xmen Patient T Cells and Hematopoietic Stem Cells
Meisel, R.
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2137 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
2137 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
Meissner, B.
546 - Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL
555 - Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia
1518 - Towards a Unified Genetic Classification System for Diffuse Large B-Cell Lymphoma (DLBCL)
2836 - Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
4166 - Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
555 - Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia
1518 - Towards a Unified Genetic Classification System for Diffuse Large B-Cell Lymphoma (DLBCL)
2836 - Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
4166 - Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL
Meissner, J.
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
Mejia Garcia, A. V.
Mejia Saldarriaga, M.
Mejia-Arangure, J. M.
Mejri, A.
Mekelenkamp, H.
Mekrakseree, B.
Mekwunye, K.
Mela Osorio, M. J.
Melaccio, A.
Melani, C.
952 - Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease
2939 - Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
4001 - Effect of Isavuconazole on Plasma and CSF Levels of Ibrutinib and Plasma Levels of Liposomal Doxorubicin Among Patients Receiving Teddi-R for CNS Lymphoma
2939 - Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
4001 - Effect of Isavuconazole on Plasma and CSF Levels of Ibrutinib and Plasma Levels of Liposomal Doxorubicin Among Patients Receiving Teddi-R for CNS Lymphoma
Melchardt, T.
561 - Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine – a Prospective Cohort Study By the AGMT
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
Melchior Heissmann, J.
Mele, N.
Melear, J.
314 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)
2893 - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
4562 - Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
2893 - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
4562 - Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
Melenhorst, J. J.
Melgar, I.
1578 - A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)
2953 - A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter’s Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
2953 - A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter’s Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
Melgar-Bermudez, E.
Meli, C.
Meli, E.
Mellenthin, L.
Mellert, K.
Mellin, R.
Mellinghoff, I. K.
Mellios, Z.
Melloni, G.
Mellqvist, U. H.
1921 - Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
2291 - Light-Chain Amyloidosis in Sweden (2011-2019): Incidence, Disease Burden, and Clinical Outcomes in Real-World Patients
2291 - Light-Chain Amyloidosis in Sweden (2011-2019): Incidence, Disease Burden, and Clinical Outcomes in Real-World Patients
Melly, B.
Melnekoff, D. T.
Melnick, A.
47 - Simultaneous Inhibition of SIRT3 and Cholesterol Homeostasis Targets AML Stem Cells By Perturbing Fatty Acid β-Oxidation and Inducing Lipotoxicity
67 - The Single-Cell Pathology Landscape of Diffuse Large B Cell Lymphoma
551 - FGFR1 Is a Novel Therapeutic Target in Relapsed/Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL)
703 - Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma
708 - DTX1 Controls Germinal Center B-Cell Development and Lymphomagenesis
67 - The Single-Cell Pathology Landscape of Diffuse Large B Cell Lymphoma
551 - FGFR1 Is a Novel Therapeutic Target in Relapsed/Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL)
703 - Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma
708 - DTX1 Controls Germinal Center B-Cell Development and Lymphomagenesis
Melnick, A.
Melo, R. C.
Melo-Cardenas, J.
Melody, M.
1666 - Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD
2050 - Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis
2970 - Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder
2050 - Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis
2970 - Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder
Meloni, A.
1034 - Chronic Hepatitis C Virus Infection Is Associated with an Increased Risk of Diabetes Mellitus in Thalassemia Major
1035 - Association between Myocardial Iron Overload and Diffuse Myocardial Fibrosis in Thalassemia Major
2354 - Cardiac Magnetic Resonance Predicts Heart Failure Mortality in Patients with Thalassemia Major
2355 - Link between Bone Marrow and Cardiac Iron Overload in Thalassemia Major
1035 - Association between Myocardial Iron Overload and Diffuse Myocardial Fibrosis in Thalassemia Major
2354 - Cardiac Magnetic Resonance Predicts Heart Failure Mortality in Patients with Thalassemia Major
2355 - Link between Bone Marrow and Cardiac Iron Overload in Thalassemia Major
Melvin, C. L.
1074 - Baseline Patient and Provider Reports of Quality of Care and Confidence Providing ED Management of Vaso-Occlusive Episodes
2190 - Dissemination and Implementation Looking at the Care Environment (DISPLACE) Study Evaluates Novel Interventions to Improve TCD (Sickle Stroke Screening) Implementation
2190 - Dissemination and Implementation Looking at the Care Environment (DISPLACE) Study Evaluates Novel Interventions to Improve TCD (Sickle Stroke Screening) Implementation
Men, L.
81 - A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
82 - Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
83 - Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
82 - Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
83 - Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
Menapace, L. A.
1174 - A Phase 3 Study to Evaluate the Efficacy and Safety of Caplacizumab without First-Line Therapeutic Plasma Exchange in Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura
2493 - The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies
- Government Careers
2493 - The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies
- Government Careers
Ménard, A.
Menard, C.
166 - Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study
2878 - Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study
2878 - Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study
Menchaca, K.
Menchikova, E. V.
Mencia Trinchant, N.
1389 - PTPN11 mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation
3863 - Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid Leukemia
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
4945 - Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation
3863 - Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid Leukemia
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
4945 - Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]
Mendelson, A.
Mendes, L.
Mendes, M.
Mendes-de-Almeida, D. P.
Mendeville, M.
Mendez, L. F.
Mendez Lopez, A.
Mendez, L. M.
Mendez, M. T.
Mendez-Garcia, E.
Mendicino, F.
Mendler, J. H.
132 - A Patient-Centered Communication Tool for Older Patients with Acute Myeloid Leukemia, Their Caregivers, and Oncologists: A Single Arm Pilot Study
1761 - Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab
3026 - Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial
4868 - Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
1761 - Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab
3026 - Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial
4868 - Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Mendonça, P.
Mendoza, A.
Mendoza, D.
Mendoza-Castrejon, J.
Mendoza-Sanchez, R.
Meneguin, T. D.
Menéndez, P.
Meng, C.
Meng, H.
Meng, J.
Meng, L.
Meng, L.
83 - Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
335 - Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
335 - Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
Meng, L.
3398 - Association between Haploidentical Hematopoietic Stem Cell Transplantation Combined with an Umbilical Cord Blood Unit and Graft-Versus-Host Disease in Pediatric Patients with Acquired Severe Aplastic Anemia
4723 - The Association of pDC Dose in Graft with CMV and EBV Infection after Allo-HSCT in Pediatric Patients: A Single-Center Experience
4723 - The Association of pDC Dose in Graft with CMV and EBV Infection after Allo-HSCT in Pediatric Patients: A Single-Center Experience
Meng, Y.
Mengarelli, A.
Menger, M. D.
Menges, M. A.
2008 - Interim Results of a Prospective Trial Testing Vaccination Against Pneumococcus before and after CD19 CAR T Cell Therapy to Optimize Humoral Immunity
2039 - Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
2039 - Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
Mengge, G.
Menghrajani, K.
Menna, G.
Menna, T.
Menna, T. N.
Menne, T. F.
732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
2029 - Improvement in Lymphoma CAR-T Outcomes over Time in the UK – CAR-T Learning Curve or Better Bridging?
4634 - First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
2029 - Improvement in Lymphoma CAR-T Outcomes over Time in the UK – CAR-T Learning Curve or Better Bridging?
4634 - First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
Mennemeyer, S.
Meno, T.
Menon, N. M.
Menon, P.
Menon, R.
1864 - Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection
4548 - Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone
4548 - Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone
Menon, V.
Menoret, E.
Menotti, S.
Mensah, A. A.
Mensah, J. E.
Mensah-Glanowska, P.
Mensing, G.
Mention, K.
Menu, E.
Menzies, T.
570 - Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant – Data from the Myeloma XI Trial
754 - Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial
1842 - The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
1873 - The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma
754 - Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial
1842 - The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
1873 - The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma
Merabet, F.
616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
Merad, M.
1685 - Bone Marrow-Derived BRAFV600E-Mutated Cells Drive Neurodegeneration in a Mouse Model of Langerhans Cell Histiocytosis
1903 - Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
4318 - Myeloid Progenitors Define Extent of Disease in Mouse Models of Histiocytic Disorders: BRAFV600E Expression in Monocyte Lineage Recapitulates Erdheim-Chester Phenotype
1903 - Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
4318 - Myeloid Progenitors Define Extent of Disease in Mouse Models of Histiocytic Disorders: BRAFV600E Expression in Monocyte Lineage Recapitulates Erdheim-Chester Phenotype
Meraviglia, S.
Mercalli, F.
Mercer, N.
Merchan, B.
Merchant, A.
Merchant, A.
Merchant, N.
Mercier, M.
Mercier-Ross, J.
Mercure-Corriveau, N.
Mercurio, V.
Meredith, D.
Merelli, I.
Merigo, F.
Merino, A.
Meriranta, L.
76 - Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
548 - Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas
734 - Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study
2617 - Oncogenic Mutational Disruption of KLHL6 Dimers Fuels B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma
548 - Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas
734 - Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study
2617 - Oncogenic Mutational Disruption of KLHL6 Dimers Fuels B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma
Merleev, A. A.
Merli, F.
733 - PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)
1566 - Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi
2214 - Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines
1566 - Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi
2214 - Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines
Merli, G.
Merli, M.
547 - Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi
949 - Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1–3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
1566 - Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi
2895 - Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy
2905 - How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia
4376 - A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region
949 - Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1–3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
1566 - Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi
2895 - Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy
2905 - How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia
4376 - A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region
Merli, P.
775 - Updated Analysis on the Outcomes of Children with Acute Leukemia (AL) Receiving an Alpha/Beta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)
4895 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study
4895 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study
Merli, P.
3279 - CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia
4721 - Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD
4721 - Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD
Merlini, G.
Merlini, G.
761 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
3244 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
3244 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
Merlino, G.
Merlotti, A.
Mernick, F.
Meron, H.
Merricks, E. P.
Merricks, E. P.
Merrill, M. H.
323 - Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
490 - A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
4931 - Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era
490 - A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
4931 - Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era
Merriman, E.
Merriweather, B.
2181 - Non-Invasive Optical Characterization of Tissue Hemodynamics in Sickle Cell Patients Undergoing Treatment with Isoquercetin
3699 - Targeting Thrombophilia in Sickle Cell Disease with Isoquercetin: Results of a Fixed Dose, Single Center, Phase II Randomized Clinical Trial
3700 - Effects of Isoquercetin on Plasma Protein Disulfide Isomerase Activity and Extracellular Vesicle Tissue Factor Antigen/Activity in Sickle Cell Disease
3699 - Targeting Thrombophilia in Sickle Cell Disease with Isoquercetin: Results of a Fixed Dose, Single Center, Phase II Randomized Clinical Trial
3700 - Effects of Isoquercetin on Plasma Protein Disulfide Isomerase Activity and Extracellular Vesicle Tissue Factor Antigen/Activity in Sickle Cell Disease
Merryman, R. W.
490 - A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
Mersi, J.
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
3138 - Spatial Transcriptomics Reveals a Multi Cellular Ecosystem in Extramedullary Multiple Myeloma
4473 - The T-Cell Metabolic Phenotype Is Dependent on Risk Status and Degree of PC Bone Marrow Infiltration in Multiple Myeloma
4502 - Pseudoprogression and Sarcoidosis-like Phenomena after CART-Cells and Bispecific Antibodies in Multiple Myeloma
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
3138 - Spatial Transcriptomics Reveals a Multi Cellular Ecosystem in Extramedullary Multiple Myeloma
4473 - The T-Cell Metabolic Phenotype Is Dependent on Risk Status and Degree of PC Bone Marrow Infiltration in Multiple Myeloma
4502 - Pseudoprogression and Sarcoidosis-like Phenomena after CART-Cells and Bispecific Antibodies in Multiple Myeloma
Merten, C.
Mertens, D.
Mertens, D.
Mertens, P.
Mertlitz, S.
Merwin, S.
Mery, D.
Merz, M.
1481 - Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation
1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia
2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
2103 - Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation
3204 - Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders
4756 - Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia
2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
2103 - Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation
3204 - Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders
4756 - Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Mesa, R.
238 - Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
627 - Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
628 - Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
1712 - Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
1728 - Mediterranean Diet Intervention in Patients with Myeloproliferative Neoplasm
1731 - Impact of Chronic Disease and Its Burden on Aspects of Quality of Life in a Unique Sub-Population of Myeloproliferative Neoplasm Patients
1733 - Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib
1735 - Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119
3028 - Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum
3031 - Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL
3477 - In Vitro and In Vivo Studies Support GFH009, a Selective CDK9 Inhibitor, As a Potential Treatment for Hematologic Cancers
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
4357 - Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
627 - Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
628 - Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial
1712 - Differential Impact of Thrombocytopenia and Anemia on Myelofibrosis (MF) Symptom Burden
1728 - Mediterranean Diet Intervention in Patients with Myeloproliferative Neoplasm
1731 - Impact of Chronic Disease and Its Burden on Aspects of Quality of Life in a Unique Sub-Population of Myeloproliferative Neoplasm Patients
1733 - Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib
1735 - Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119
3028 - Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum
3031 - Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL
3477 - In Vitro and In Vivo Studies Support GFH009, a Selective CDK9 Inhibitor, As a Potential Treatment for Hematologic Cancers
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
4351 - The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study
4357 - Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
Mesa-Núñez, C.
Mesaros, C.
Mesaros, L.
Meshinchi, S.
Meshinchi, S.
66 - Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML
1467 - Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
2718 - Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial
4031 - Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
4586 - Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation
1467 - Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
2718 - Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial
4031 - Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
4586 - Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation
Mesquita, G. L.
Messer, C.
Messina, A. J.
Messina, G.
Messina, M.
Messinger, Y. H.
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
3530 - The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis
3530 - The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis
Mestre-Durán, C.
1997 - A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
4704 - Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism
4704 - Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism
Metais, J. Y.
Metayer, C.
Metheny, L.
778 - Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
3224 - African American Race Is a Potential Favorable Biologic Factor That Impacts Clinical Outcome for Patients with Multiple Myeloma
3320 - Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy
4686 - PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
3224 - African American Race Is a Potential Favorable Biologic Factor That Impacts Clinical Outcome for Patients with Multiple Myeloma
3320 - Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy
4686 - PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
Metidji, A.
Metois, A.
Metts, J.
Metz, C.
Metzelder, S. K.
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
979 - Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML
979 - Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML
Metzeler, K. H.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
280 - Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
388 - German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
1481 - Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation
1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia
2103 - Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation
2811 - Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells
4018 - Acute Myeloid Leukemia with Isolated Trisomy 4 Is Characterized By Frequent Mutations of TET2 and a Distinct DNA Methylation Signature
4756 - Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
280 - Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
388 - German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
1481 - Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation
1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia
2103 - Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation
2811 - Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells
4018 - Acute Myeloid Leukemia with Isolated Trisomy 4 Is Characterized By Frequent Mutations of TET2 and a Distinct DNA Methylation Signature
4756 - Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Metzeler, K. H.
386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
1745 - Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics
2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
1745 - Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics
2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
Metzeler, K. H.
2129 - Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation
2319 - Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
4077 - Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
2319 - Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
4077 - Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
Metzger, M.
Metzgeroth, G.
1316 - Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms
1727 - Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis
1744 - Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes
4416 - Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival
1727 - Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis
1744 - Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes
4416 - Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival
Metzler, A. D.
Metzler, I. V.
116 - Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
755 - Portraying Immunity to Sars-Cov-2 after mRNA-Vaccination in Patients with Multiple Myeloma
755 - Portraying Immunity to Sars-Cov-2 after mRNA-Vaccination in Patients with Multiple Myeloma
Metzler, M.
Metzner, M.
220 - A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results
493 - Genotyping of Multiple Genomic Loci with Chromatin Accessibility Profiling in Single Cells Links Clonal Hierarchy with Epigenetic Variation in Acute Myeloid Leukemia
653 - Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia
925 - Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
1482 - Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2-Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study
2545 - Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point
3912 - Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia
493 - Genotyping of Multiple Genomic Loci with Chromatin Accessibility Profiling in Single Cells Links Clonal Hierarchy with Epigenetic Variation in Acute Myeloid Leukemia
653 - Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia
925 - Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
1482 - Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2-Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study
2545 - Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point
3912 - Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia
Meunier, M.
Meunier, S.
Meverden, R. A.
Meydan, C.
Meyer, A. E.
Meyer, A.
Meyer, A.
Meyer, C. L.
3414 - Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data
3421 - Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
4520 - Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California
3421 - Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
4520 - Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California
Meyer, C.
Meyer, E. H.
265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
3408 - Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
3408 - Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
Meyer, J.
Meyer, J.
Meyer, L. M.
Meyer, L. K.
Meyer, L.
Meyer, N. J.
Meyer, R.
Meyer, S. C.
Meyer, S. E.
Meyers, J.
Meyers, M. L.
63 - The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
Meza, M.
Meza-Zepeda, L.
Meznarich, J.
Mezzadra, R.
Mezzasoma, F.
Mfarrej, B.
Mhaldien, L.
Mhaskar, R.
Mhaskar, R.
Mhibik, M.
Mi, J. Q.
1417 - The First Report of Third-Generation TKI Olverembatinib in Adult Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease
3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
3357 - Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
4049 - A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial
3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
3357 - Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
4049 - A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial
Mi, Y.
1256 - Avatrombopag Added to Standard Immunosuppressive Therapy for Severe Aplastic Anemia
2066 - Herombopag for Enhancement of Platelet Engraftment in Patients Undergoing Hematopoietic Stem Cell Transplantation
2572 - Immunosuppressive Therapy-Response Predicting Scoring System for Severe Aplastic Anemia
2575 - Hematological Response to Avatrombopag Switch in Thrombopoietin Receptor Agonist-Refractory Aplastic Anemia
3890 - Anti-Human T Lymphocyte Porcine Immunoglobulin Combined with Cyclosporine As First-Line Immunosuppressive Therapy for Severe Aplastic Anemia in China: A Large Single-Center, 10-Year Retrospective Study
3894 - Hetrombopag Add to Porcine ATG and Cyclosporine for Aplastic Anemia: Early Outcomes of a Prospective Pilot Study
2066 - Herombopag for Enhancement of Platelet Engraftment in Patients Undergoing Hematopoietic Stem Cell Transplantation
2572 - Immunosuppressive Therapy-Response Predicting Scoring System for Severe Aplastic Anemia
2575 - Hematological Response to Avatrombopag Switch in Thrombopoietin Receptor Agonist-Refractory Aplastic Anemia
3890 - Anti-Human T Lymphocyte Porcine Immunoglobulin Combined with Cyclosporine As First-Line Immunosuppressive Therapy for Severe Aplastic Anemia in China: A Large Single-Center, 10-Year Retrospective Study
3894 - Hetrombopag Add to Porcine ATG and Cyclosporine for Aplastic Anemia: Early Outcomes of a Prospective Pilot Study
Miah, K.
Mian, A.
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
4445 - Incidence of Secondary Hematological Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: An Analysis of SEER Database
4445 - Incidence of Secondary Hematological Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: An Analysis of SEER Database
Mian, H. S.
117 - Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
171 - Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study
173 - Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada
991 - Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2288 - Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
3248 - Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
171 - Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study
173 - Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada
991 - Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2288 - Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
3248 - Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
Mian, M. A.
Mian, O.
Mian, S.
Miano, M.
Miano, T. A.
Miao, H.
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
2022 - Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
4660 - 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
2022 - Real-World Bridging Therapy (BT) of Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Systematic Literature Review (SLR) and Meta-Analysis
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
4660 - 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Miao, M.
1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
2574 - Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study
4146 - Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia
2574 - Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study
4146 - Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia
Miao, X.
1911 - Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
3228 - Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab
3228 - Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab
Miao, Y.
1792 - Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)
1811 - Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia
3104 - Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
3108 - Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL
1811 - Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia
3104 - Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
3108 - Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL
Micalizzi, C.
Micallef, I. N.
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
4745 - Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR- Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation
4745 - Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR- Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation
Miccio, A.
Michael, A. O.
Michael, M. D.
Michaelis, L. C.
65 - Lintuzumab-Ac225 with Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features
2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia
2689 - Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
4951 - Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)
- Recommendations for less-intensive therapy in older adults and future directions
- Plenary Introducer
2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia
2689 - Assessment of Comorbidities and Their Association with Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL)Using Various Comorbidity-Based Scoring Systems
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
4951 - Outcomes of Patients Treated with Low-Intensity Re-Induction Therapy for Persistent Disease after a Single Intensive Induction Cycle for Newly Diagnosed Acute Myeloid Leukemia (AML)
- Recommendations for less-intensive therapy in older adults and future directions
- Plenary Introducer
Michaelis, S.
Michaels, P.
Michaels, T.
Michalek, J. E.
1650 - Identifying Demographic and Disease Related Differences in Hispanic Vs Non-Hispanic Patients with Post Transplant Lymphoproliferative Disorders
2902 - Current Status of Racial and Ethnic Disparities for Follicular Lymphoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis with Emphasis on Hispanics
2943 - Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients
2968 - Demographics, Analysis of Survival and Outcomes of Primary Effusion Lymphomas: A National Retrospective Study with a Focus on Hispanics
2979 - Racial and Ethnic Disparities for Diffuse Large B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis with Emphasis on Hispanics
4921 - Current Status of Demographics and Survival Outcomes of Cutaneous T-Cell Lymphoma - Not Otherwise Specified in United States: A Contemporary Population Based Study with Focus on Hispanics
2902 - Current Status of Racial and Ethnic Disparities for Follicular Lymphoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis with Emphasis on Hispanics
2943 - Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients
2968 - Demographics, Analysis of Survival and Outcomes of Primary Effusion Lymphomas: A National Retrospective Study with a Focus on Hispanics
2979 - Racial and Ethnic Disparities for Diffuse Large B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis with Emphasis on Hispanics
4921 - Current Status of Demographics and Survival Outcomes of Cutaneous T-Cell Lymphoma - Not Otherwise Specified in United States: A Contemporary Population Based Study with Focus on Hispanics
Michali, E.
Michallet, A. S.
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
2750 - Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring
2952 - Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
3124 - Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53
2750 - Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring
2952 - Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
3124 - Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53
Michallet, M.
1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
2750 - Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
2750 - Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
Michalopoulou, A.
Michaud, L.
Michaud, L.
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
Michaud, N. R.
Michel, B. S.
Michel, G.
776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
905 - Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors
905 - Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors
Michel, M.
3 - Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
23 - Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry
1012 - Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience
1201 - Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)
2446 - Long-Term Outcome of Adolescents and Young Adults with Chronic Primary Immune Thrombocytopenia (ITP)
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
3653 - Drug-Induced Autoimmune Hemolytic Anemia: Detection of New Signals in the World Pharmacovigilance Database and Risk Assessment in a Nationwide Cohort Study in France
23 - Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry
1012 - Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience
1201 - Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)
2446 - Long-Term Outcome of Adolescents and Young Adults with Chronic Primary Immune Thrombocytopenia (ITP)
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
3653 - Drug-Induced Autoimmune Hemolytic Anemia: Detection of New Signals in the World Pharmacovigilance Database and Risk Assessment in a Nationwide Cohort Study in France
Michelis, F. V.
2127 - Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
3395 - ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies
4707 - Impact of Cytomegalovirus (CMV) Sero-Conversion Pre Allogeneic Stem Cell Transplant on Post-Transplant Outcomes
4737 - Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse
3395 - ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies
4707 - Impact of Cytomegalovirus (CMV) Sero-Conversion Pre Allogeneic Stem Cell Transplant on Post-Transplant Outcomes
4737 - Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse
Michielin, F.
Michmerhuizen, N. L.
Michor, F.
Michot, J. M.
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
2875 - Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC‑99282
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
2875 - Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC‑99282
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
Micillo, M.
Micklethwaite, K. P.
Mickute, G.
Mico', M. C.
3413 - Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia
4765 - Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis
4765 - Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis
Micol, J. B.
Micozzi, A.
Middeke, J. M.
4 - In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
979 - Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
979 - Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
Middeldorp, S.
Middelkamp, S.
Middleton, C.
Middleton, E.
Mielcarek, M.
Mielke, S.
Mierski, J.
Miesbach, W. A.
Miesbach, W. A.
2139 - Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B
2141 - Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up
2142 - Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061)
2141 - Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up
2142 - Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061)
Miething, C.
Miettinen, J. J.
46 - Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
2673 - A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma
4799 - The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies
429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
2673 - A Potential Role of NK Cells and ABCB9 in Modulating the Response to Melflufen in Multiple Myeloma
4799 - The Novel Peptide Drug Conjugate OPDC3 Is Highly Active in Different Hematological Malignancies
Migdady, Y.
1778 - A Retrospective Validation Study Comparing the IPSS-M and IPSS-R Risk Stratification Scores in Primary and Secondary Myelodysplastic Syndrome (MDS)
3372 - Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34+-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells
3372 - Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34+-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells
Miggiano, M. C.
623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
1700 - Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
1700 - Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
Migkou, M.
474 - Prognostic Significance of Circulating Plasma Cells Detected By Next Generation Flow Cytometry in Light (AL) Chain Amyloidosis
647 - Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3221 - The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
647 - Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3221 - The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
Migliaccio, A. R.
Migliaccio-Walle, K.
Miglino, M.
4026 - Prognostic Relevance of Minimal Residual Disease in Therapy Related and Secondary Acute Myeloid Leukemia Receiving CPX-351 or Fludarabine-Based Induction
4326 - Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
4326 - Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
Migone De Amicis, M.
Miguel-García, C.
Miguet, L.
Mihaljevic, B.
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1200 - Tissue Factor Positive Extracellular Vesicles and Risk of Thromboembolism in Diffuse Large B-Cell Lymphoma: A Prospective Exploratory Study
1200 - Tissue Factor Positive Extracellular Vesicles and Risk of Thromboembolism in Diffuse Large B-Cell Lymphoma: A Prospective Exploratory Study
Mihas, P.
172 - "...Paying to be a Patient in the Hospital and the Parking Lot": Dyadic Perspectives on Multiple Myeloma-Related Healthcare Access Barriers
380 - "If You Don’t Trust Your Doctor That Much...You’d Feel Less Confident Doing a Research Study": Factors Influencing Black Patient Participation in Hematology Trials
383 - "You Have Your Knowledge, but I Have My Knowledge of My Body": The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials
380 - "If You Don’t Trust Your Doctor That Much...You’d Feel Less Confident Doing a Research Study": Factors Influencing Black Patient Participation in Hematology Trials
383 - "You Have Your Knowledge, but I Have My Knowledge of My Body": The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials
Miida, T.
Mijuskovic, M.
Mikdar, M.
Mikesch, J. H.
4 - In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
3377 - Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
3377 - Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease
Mikhaeel, G.
Mikhael, J. R.
Miki, K.
Mikita-Geoffroy, J.
Mikkelsen, M.
Mikkilineni, L.
Miklos, D. B.
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
640 - Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
659 - Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
982 - CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study
2018 - A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies
2090 - Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
2849 - Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
4199 - Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
640 - Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
659 - Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
982 - CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study
2018 - A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies
2090 - Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
2849 - Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
3345 - Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
4199 - Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
Mikulasova, A.
Mikulenkova, D.
Mikulski, D.
1388 - A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL – a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
Milan, E.
Milan Salvatierra, A.
Milanesi, C.
Milani, P.
Milano, A.
Milano, F.
369 - Late Graft Failure in MDS and Acute Leukemia Patients Receiving Allogenic Hematopoietic Cell Transplantation with Post Transplant Cyclophosphamide As Gvhd Prophylaxis
3316 - Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
3316 - Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Mild, G.
Miles, B.
Miles, J. S.
Miles, L. A.
Miles, R. R.
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
Milic, N.
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1200 - Tissue Factor Positive Extracellular Vesicles and Risk of Thromboembolism in Diffuse Large B-Cell Lymphoma: A Prospective Exploratory Study
1200 - Tissue Factor Positive Extracellular Vesicles and Risk of Thromboembolism in Diffuse Large B-Cell Lymphoma: A Prospective Exploratory Study
Militano, O.
Milite, S.
Mill, C. P.
204 - Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression
2601 - Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1
2663 - Bruton’s Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors
3967 - Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53
3973 - Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background
2601 - Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1
2663 - Bruton’s Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors
3967 - Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53
3973 - Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background
Mill, J.
Millen, R.
Millenson, M.
Miller, A.
Miller, C.
1424 - Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia
4055 - Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
4055 - Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
Miller, C.
Miller, C. A.
2600 - A Comprehensive Reassessment of the Direct DNA Binding Sites of PML-Rara within the Genomes of Primary Hematopoietic Progenitor Cells, and Their Effects on Chromatin Structure and Gene Expression
2618 - Nucleolar Stress Plays a Key Role in the Pathogenesis of T Cell Acute Lymphoblastic Leukemia
3266 - Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma
2618 - Nucleolar Stress Plays a Key Role in the Pathogenesis of T Cell Acute Lymphoblastic Leukemia
3266 - Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma
Miller, D. E.
Miller, E. J.
Miller, G. E.
Miller, J. P.
Miller, J.
Miller, J.
Miller, J.
Miller, K.
720 - Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation
994 - Geographical Barriers to Accessing Specialty Cancer Care Among Adolescents and Young Adults with Acute Lymphoblastic Leukemia
994 - Geographical Barriers to Accessing Specialty Cancer Care Among Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Miller, K.
2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
4909 - Identifying Patterns of Neurocognitive Dysfunction through Direct Comparison of Patients with Leukemia, CNS Tumors, and Sickle Cell Disease
4909 - Identifying Patterns of Neurocognitive Dysfunction through Direct Comparison of Patients with Leukemia, CNS Tumors, and Sickle Cell Disease
Miller, L.
Miller, L.
Miller, M. P.
Miller, M. F.
Miller, P. G.
Miller, R. A.
Miller, R. E.
Miller, R. M.
Miller, S.
433 - PAX5 Epigenetically Orchestrates CD58 Transcription and Modulates Blinatumomab Response in Acute Lymphoblastic Leukemia
919 - Mutational Permutations of a Single Amino Acid Exert Divergent Phenotypic Effects in Human, Mice, and Cellular Models of SAMD9L Bone Marrow Failure Disorder
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
3465 - Increased Potency and Uniformity of Fetal Hemoglobin Induction from Base Editing Compared to Cas9 Nuclease
3983 - Genetic and Epigenetic Cis-Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia
919 - Mutational Permutations of a Single Amino Acid Exert Divergent Phenotypic Effects in Human, Mice, and Cellular Models of SAMD9L Bone Marrow Failure Disorder
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
3465 - Increased Potency and Uniformity of Fetal Hemoglobin Induction from Base Editing Compared to Cas9 Nuclease
3983 - Genetic and Epigenetic Cis-Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia
Miller, S.
Miller, T.
389 - Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns
4941 - Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
4941 - Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
Miller, T. P.
Miller, Y. M.
Miller, MD, J. S.
114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
3990 - B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma
4623 - A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML
- Novel Immunomodulatory Agents to Harness NK Cell Mediated Anti-Tumor Responses
3990 - B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma
4623 - A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML
- Novel Immunomodulatory Agents to Harness NK Cell Mediated Anti-Tumor Responses
Miller-Chism, C. N.
Millholland, J.
Millman, S. E.
Mills, E.
Mills, J.
172 - "...Paying to be a Patient in the Hospital and the Parking Lot": Dyadic Perspectives on Multiple Myeloma-Related Healthcare Access Barriers
380 - "If You Don’t Trust Your Doctor That Much...You’d Feel Less Confident Doing a Research Study": Factors Influencing Black Patient Participation in Hematology Trials
383 - "You Have Your Knowledge, but I Have My Knowledge of My Body": The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials
380 - "If You Don’t Trust Your Doctor That Much...You’d Feel Less Confident Doing a Research Study": Factors Influencing Black Patient Participation in Hematology Trials
383 - "You Have Your Knowledge, but I Have My Knowledge of My Body": The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials
Mills, K. I.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
1349 - New Mechanistic and Therapeutic Insights into Purified Phospholipase A2 from Pseudechis Australis Snake Venom - a Novel Anticancer Agent for the Treatment of Precursor B-Cell Acute Lymphoblastic Leukaemia
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
3006 - UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model
3480 - Multiplex Drug Screening Identifies a Novel Therapeutic Backbone for the Treatment of Acute Myeloid Leukaemia
3914 - CHD4 Loss Alters Chromatin Accessibility Giving Rise to Sensitivity to DNA Damage Repair Compounds in Acute Myeloid Leukaemia
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
1349 - New Mechanistic and Therapeutic Insights into Purified Phospholipase A2 from Pseudechis Australis Snake Venom - a Novel Anticancer Agent for the Treatment of Precursor B-Cell Acute Lymphoblastic Leukaemia
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
3006 - UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model
3480 - Multiplex Drug Screening Identifies a Novel Therapeutic Backbone for the Treatment of Acute Myeloid Leukaemia
3914 - CHD4 Loss Alters Chromatin Accessibility Giving Rise to Sensitivity to DNA Damage Repair Compounds in Acute Myeloid Leukaemia
Milne, K.
Milne, T. A.
3912 - Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia
3944 - Establishment and Characterization of a Model of Acquired Resistance to DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic Leukemia Cells
3944 - Establishment and Characterization of a Model of Acquired Resistance to DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic Leukemia Cells
Milner, E.
Milojkovic, D.
1703 - Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia
3025 - Real-World Experience of Asciminib: Factors Associated with Response
4327 - A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
4332 - Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study
3025 - Real-World Experience of Asciminib: Factors Associated with Response
4327 - A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
4332 - Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study
Milone, G. A.
Milone, G.
771 - Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
3413 - Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia
3431 - Sars-Cov-2 Vaccination Response Monitoring in Lymphoma and Multiple Myeloma Patients Following Standard Versus High-Dose Chemotherapy and Autologous Stem Cell Transplantation
4765 - Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis
3413 - Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia
3431 - Sars-Cov-2 Vaccination Response Monitoring in Lymphoma and Multiple Myeloma Patients Following Standard Versus High-Dose Chemotherapy and Autologous Stem Cell Transplantation
4765 - Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis
Milosevic, I.
Milosevic, I.
Milosevic, J.
Miltgen, N.
Miltiadous, O.
Milton, A.
213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
1410 - Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia—6-Year Follow-up Results
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
1410 - Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia—6-Year Follow-up Results
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
Milton, D. R.
115 - Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
2248 - The Natural History of Heparin Induced Thrombocytopenia (HIT) in Cancer Patients
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
2248 - The Natural History of Heparin Induced Thrombocytopenia (HIT) in Cancer Patients
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
Mims, A. S.
386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
536 - Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study
789 - Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
1326 - The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)
1425 - A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
1458 - Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial
1771 - Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
2227 - Safety and Feasibility of Outpatient High-Dose Cytarabine Consolidation in AML Patients
2270 - Patterns of Neuropathy in ALL Patients Treated with Vincristine Based Regimens with and without Tyrosine Kinase Inhibitors
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
2760 - Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
4087 - Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)
- Novel Investigational Approaches for High Risk Molecular Subsets: TP53, MLL, FLT3
536 - Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study
789 - Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
1326 - The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)
1425 - A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
1458 - Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial
1771 - Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
2227 - Safety and Feasibility of Outpatient High-Dose Cytarabine Consolidation in AML Patients
2270 - Patterns of Neuropathy in ALL Patients Treated with Vincristine Based Regimens with and without Tyrosine Kinase Inhibitors
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
2760 - Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
4087 - Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)
- Novel Investigational Approaches for High Risk Molecular Subsets: TP53, MLL, FLT3